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ABSTRACT 
 
Jiyoung Cha: The Role and Mechanism of Fibroblast Growth Factor 
Receptor 2 in Cellular Transformation 
(Under the direction of Channing J. Der) 
 
 Our laboratory recently identified fibroblast growth factor receptor 2 
(FGFR2) as a transforming gene using a cDNA expression library screen for novel 
oncogenes expressed in human breast carcinoma cells. An important feature and 
mode of FGFR2 function is the expression of structural variants of FGFR2 that are 
encoded by transcripts that arise alternative gene splicing.  The tissue-restricted 
nature of some splice variant transcripts, together with the functional and biological 
differences of FGFR2 splice variant protein products, provides mechanisms of 
regulation of receptor function distinct from regulation of expression of receptor 
ligands.  The first major splicing event occurs in the sequences encoding the amino-
terminal extracellular domain, involving the third immunoglobulin (Ig-III)-like domain, 
to generate either the epithelial cell-specific IIIb or mesenchymal cell-specific IIIc 
isoforms.  The second major splicing occurs in sequences that encode the 
intracellular carboxyl-terminus, resulting in three splice variants that differ in their 
carboxyl-terminal sequences have been identified (designated C1, C2 and C3). My 
studies have focused on defining the role of these two major alternative splicing 
 ii
events in FGFR2 function and oncogenesis. First, I found preferential expression of 
the mesenchymal-specific FGFR2 IIIc splice variant in invasive breast carcinomas.  
FGFR2 IIIc expression was associated with loss of expression of epithelial cell-
specific and the gain of expression of mesenchymal cell-specific markers. These 
observations suggest that IIIb to IIIc exon switching may be involved in tumor cell 
invasion and metastasis.   Additionally, I evaluated the signaling and transforming 
activity of the epithelial cell-specific isoform in mammary epithelial cells.  Second, I 
compared the transforming potency of the C1, C2 and C3 splicing variants and 
found that a hierarchy of transforming activity that correlated with progressive loss of 
carboxyl terminal sequences.  I determined that one mechanism for the enhanced 
transforming activity of FGFR2 IIIb C3 involves loss of the 770YLDL sorting motif and 
impaired internalization and a gain of ligand-independent FRS2 activation. Together, 
my studies provide further evidence for alternative gene splicing as a mechanism for 
causing aberrant FGFR2 function in promoting human oncogenesis. 
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Chapter 1: Introduction 
The direction of my dissertation research was based on the unpublished 
identification of the fibroblast growth factor receptor 2 (FGFR2) receptor tyrosine 
kinase (RTK), isoform IIIb C2, in an expression library screen for novel oncogenes 
expressed in human breast cancers.  Since the aberrant expression and function of 
RTKs is a widespread and common mechanism of human oncogenesis, my studies 
have focused on elucidating the biological activities and signaling mechanisms by 
which FGFR2 may promote the uncontrolled proliferation of human cancer cells.  In 
this introduction, I first provide an overview of RTKs and their involvement in human 
cancers and I summarize some of the key signaling mechanisms by which RTKs 
regulate normal and neoplastic cell growth.   I then focus on the FGFR family of 
RTKs and their roles in human developmental disorders and cancer. 
I. Receptor Tyrosine Kinases (RTKs) 
A. Introduction to RTKs. 
RTKs play a critical role in the regulation of multiple cellular processes 
including cell proliferation, differentiation, survival, migration and angiogenesis (1-4). 
RTKs contain an extracellular ligand binding domain that is usually glycosylated. The 
extracellular domain is connected to the cytoplasmic kinase domain by a single 
transmembrane helix. The cytoplasmic domain contains a protein tyrosine kinase 
(PTK) domain and carboxyl-terminal regulatory sequences that are subjected to 
autophosphorylation (Fig.1-1).  With the exception of the insulin receptor (IR) family 
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of RTKs, all known RTKs are monomers in the cell membrane. Members of the IR 
family are disulfide linked dimers of two polypeptide chains forming a heterodimer 
(Fig.1-2).  
In general, signalling by RTKs requires ligand-induced receptor dimerization, 
which results in tyrosine autophosphorylation of their cytoplasmic domains. Tyrosine 
autophosphorylation sites serve as binding sites for Src homology 2 (SH2) and 
protein tyrosine-binding (PTB) domains that are found on a diverse variety of 
cytoplasmic signaling proteins. Signaling proteins containing SH2 and PTB domains 
are modular in nature. Many of these proteins possess intrinsic enzymatic activities 
and addition protein-protein modules that can interact with other signaling molecules. 
Examples of protein modules involved in protein–protein interaction commonly found 
on signaling proteins are SH3, WW, LIM, PX, EH, EVH1, and PDZ domains. Protein 
modules involved in membrane signaling can also recognize molecules other than 
proteins. For example, pleckstrin homology (PH) domains recognize specific plasma 
membrane-associated phospholipids and thus allow the target protein to translocate 
to the membrane, where they can be activated by other signaling molecules (Fig.1-
1). A large family of SH2/PTB domain–containing proteins possesses intrinsic 
enzymatic activities. For instance, Src kinases and phospholipase Cγ (PLCγ) 
possess PTK and phospholipase activity, respectively (Fig.1-1). On the other hand, 
another family of SH2 domain-containing proteins, so-called adaptor proteins, does 
not possess intrinsic enzymatic activities. These adaptor proteins (e.g., Grb2, Nck, 
Crk, Shc) utilize their SH2 and/or SH3 domains to interact with effector molecules 
that are involved in the regulation of cytoplasmic signal transduction networks.
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Figure 1-1. The basic modular anatomy of RTKs.  
RTKs contain an extracellular ligand binding domain that is usually glycosylated. The 
extracellular domain is connected to the cytoplasmic kinase domain by a single 
transmembrane helix. The cytoplasmic domain contains a protein tyrosine kinase 
(PTK) domain and carboxyl-terminal regulatory sequences. Tyrosine 
autophosphorylation sites serve as binding sites for SH2 and PTB domains found on 
a diverse variety of cytoplasmic signaling proteins.  
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 For example, the adaptor protein Grb2 binds to tyrosine autophosphorylation sites 
of activated RTKs via its SH2 domain and recruits the Ras guanine nucleotide 
exchange factor (GEF) Sos via its SH3 domains and recognition of proline-rich 
sequences on Sos (4, 5).  
Another important family of proteins that involved in relaying signals from the 
activated receptors to downstream pathways is docking proteins (Fig. 1-3). Docking 
proteins contain a membrane targeting signal in their amino-termini and multiple 
phosphorylatable tyrosine sites in their carboxyl-termini. Whereas some docking 
proteins are attached to the cell membrane by a myristoyl fatty acid anchor (e.g., 
fibroblast receptor substrate 2 (FRS2)), most docking proteins are associated with 
the cell membrane via PH domains found in their amino-termini (e.g., insulin 
receptor substrate (IRS), Gab, Dok). In addition to the membrane targeting signal, 
most docking proteins contain specific domains such as PTB domains that allow the 
docking proteins to bind to the tyrosine phosphorylated receptors. Thus, docking 
proteins can function as platforms for the recruitment of signaling proteins to the 
activated RTKs. For instance, IRS binds to the activated insulin receptor (IR) via its 
PTB domain and recruits SH2-domain containing signaling molecules to the 
phosphorylated tyrosine residues in its carboxyl-terminus (4, 6). 
B. Intracellular signaling pathways regulated by RTKs 
The Ras-Raf-MEK-ERK mitogen-activated protein kinase (MAPK) pathway is 
generally considered to be one of the most central and important membrane-to- 
nucleus signaling pathways in eukaryotes (7). Upon ligand stimulation, the Grb2 
adaptor protein binds to phosphorylated tyrosine residues of RTKs via its SH2 
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Figure 1-2. Receptor tyrosine kinase (RTK) families. 
The extracellular ligand-binding domain of FGFR is composed of three 
immunoglobulin (Ig) like domains and a cluster of acidic and serine/threonine amino 
acids known as the “acid box” between Ig-I and Ig-II domains.   
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domain and forms complex with Sos via it SH3 domain (Figure 1-4). Recruitment of 
the Grb2/Sos complex to activated RTKs allows the normally cytosolic Sos to 
translocate to the plasma membrane where Sos can stimulate the exchange of GTP 
for GDP on the plasma membrane-bound small G protein Ras. Alternatively, the 
Grb2/Sos complex can be recruited to the plasma membrane by binding to the 
docking proteins such as IRS or FRS2 that become tyrosine phosphorylated in 
response to activation of  RTKs such as FGFR and IR family of RTKs. Once 
activated, Ras-GTP interacts with a multitude of effector proteins, with the Raf 
serine/threonine kinases, the phosphatidylinositol 3-kinases (PI3Ks), and the 
RalGEFs the best characterized and understood. Activated Raf activates the MEK1 
and MEK2 dual specificity protein kinases by phosphorylation on tandem serine 
residues in the activation loop of the kinase domain. Then, activated MEK stimulates 
ERK1 and ERK2 activation by phosphorylation on Thr and Tyr residues in the 
activation loop of their kinase domains. Activated ERK MAPKs then translocate into 
the nucleus where they phosphorylate and activate Ets family and other transcription 
factors, to cause changes in gene expression that regulate cell proliferation and 
survival (4, 8). The PI3K lipid kinases can be also activated by RTKs (9). The class I 
PI3Ks are comprised of heterodimers that consist of a regulatory subunit p85 and 
catalytic subunit p110. The regulatory subunit p85 contains an SH2 domain that can 
bind to the phosphorylated tyrosine residues of activated RTKs and recruit PI3K to 
the plasma membrane (Fig. 1-4). Alternatively, activated Ras can bind directly to the 
p110 subunit and recruit the enzyme to the plasma membrane. 
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Figure 1-3. Docking proteins function as platforms for the recruitment of 
signaling proteins to the activated RTKs 
Docking proteins contain a membrane targeting signal in amino-termini and multiple 
phosphorylatable tyrosine sites in carboxyl-termini. Whereas some docking proteins 
are attached to the cell membrane by a myristyl anchor (FRS2), most docking 
proteins are associated with the cell membrane via a PH domain at their amino-
terminus (IRS, Gab. Dok). Some docking proteins (FRS2, IRS) contain PTB domains 
that allow the docking proteins to bind to the tyrosine phosphorylated receptors.  
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 Activated PI3K catalyses the phosphorylation of  phosphatidylinositols (PtdIns), 
including PtdIns(4)P and PtdIns(4,5)P2, and converted to PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3, respectively. Subsequently, PtdIns(3,4,5)P3 recruits downstream 
signaling proteins that contain PH domains. The most well characterized signaling 
proteins activated by PI3K-generated PtdIns(3,4,5)P3 are the serine/threonine 
kinases Akt (also called protein kinase B; PKB) and phosphoinositide-dependent 
kinase 1 (PDK1). Once PI3K is activated, the plasma membrane-associated 
PtdIns(3,4,5)P3 interacts with the PH domains of Akt and PDK1 and recruit these 
two proteins together at the plasma membrane where PDK1 and other kinases 
phosphorylate Akt. These phosphorylations activate Akt and activated Akt then 
phosphorylates other proteins that are involved in cell growth, cell migration, and cell 
survival. For example, it has been shown that Akt activation leads to phosphorylation 
and inactivation of apoptotic protein Bad by creating a binding site for 14-3-
3 proteins and preventing Bad from binding to Bcl-2 family members Bcl-2 and Bcl-
XL. Similarly, activated Akt phosphorylates the Forkhead-related transcription factor 
1 (FKHR-L1) and creates a binding site for the 14-3-3 family of proteins. Since the 
complex of FKHR-L1 and 14-3-3 is retained in the cytosol, FKHR-L1 is inactive and 
cannot stimulate transcription of target genes. Another well characterized Akt target 
protein is glycogen synthase kinase-3 (GSK3) that is constitutively active in 
unstimulated cells.  Phosphorylation of GSK3 by Akt inactivates GSK3, resulting in 
the activation of pathways that are normally inhibited by GSK3. The termination of 
PI3K signaling by degradation of PtdIns(3,4,5)P3 can be mediated by PTEN and 
SHIP, two phosphoinositide-specific phosphatases that dephosphorylate the 3′ and 
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Figure 1-4. Intracellular signaling pathways regulated by RTKs.  
The Ras-Raf-MEK-ERK MAPK and the PI3K-Akt pathways are the two most 
important signaling pathways regulated by RTKs that promote cell proliferation and 
cell survival. 
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 5′ positions of the inositol ring of phosphoinositides, respectively. Loss of the PTEN 
tumor suppressor protein, causing PI3K activation, has been implicated in cancer 
development (9, 10).   The importance of the Raf-MEK-ERK and PI3K-Akt signaling 
pathways in RTK-mediated growth transformation is also supported by the discovery 
of mutationally-activated B-Raf and p110 alpha in human cancers (11, 12). 
 
C. Negative regulation of RTKs 
To maintain normal cell homeostasis, the activity of RTKs must be tightly 
regulated and appropriately balanced. The failure of negative regulation of RTKs can 
lead to aberrant activation of RTK signaling and may contribute to cancer 
development. Several mechanisms exist for the negative regulation of RTK activity 
after ligand stimulation, including receptor downregulation and inhibition by tyrosine 
phosphatases. 
Receptor downregulation is a major mechanism of negative regulation of 
RTKs (13, 14). Ligand binding to RTKs induces clathrin-dependent receptor 
endocytosis, following migration to multivesicular bodies and degradation in the 
lysosomal compartment. One of the most important signaling proteins involved in 
this process is the Cbl ubiquitin ligase. Subsequent to the activation of several RTKs 
such as epidermal growth factor receptor (EGFR), platelet-derived growth factor 
receptor (PDGF), and hepatocyte growth factor receptor (HGFR), Cbl is recruited to 
the phosphorylated tyrosine residue of activated RTK via its SH2 domain. Then, Cbl 
becomes phosphorylated on a tyrosine residue adjacent to the RING finger domain 
that has E3 ubiquitin ligase activity. This leads to activation of the ubiquitin E3 ligase 
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function of Cbl and following receptor ubiquitination by Cbl. Receptor ubiquitination 
facilitates endocytosis of the RTK via clathrin-coated pits and targets the RTK to the 
degradation pathway, thus contributing to signal attenuation.  In Chapter Three, I 
evaluate the possible role of Y770, which is part of a putative YXXL motif that may 
regulate receptor internalization and degradation, in aberrant FGFR2 signaling in 
cancer (Fig. 1-10). 
Protein tyrosine phosphatases (PTP) play an important role in regulating 
RTKs activity and their downstream signaling pathways (15, 16). Dephosphorylation 
of activation loop sites in RTKs leads to inactivation of the kinase domain and 
inhibition of RTK activity. While receptor downregulation causes definitive inhibition 
of signaling, dephosphorylation of RTK leads to transient and reversible inhibition 
that interferes with the strength and duration of the signal in a defined time period. 
Although most of PTPs are involved in the negative regulation of RTK signaling, 
some PTPs also function as positive regulators of RTK signal transduction. For 
example, the SH2 domain-containing PTP, SHP2, is an essential mediator of 
signaling for several RTKs.  
 
D. RTKs as therapeutic targets for target-based anti-cancer drug 
development             
When aberrantly activated, by mutation or overexpession in cancer, many 
RTKs can become potent oncoproteins. The most well chracterized RTKs implicated 
in the cancer development are the EGFR family of RTKs (17, 18). The EGFR family 
consists of four RTKs, EGFR/ErbB1, HER2(neu)/ ErbB2, HER3/ErbB3 , and 
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HER4/ErbB4 (19). While several ligands (e.g., EGF, TGFα, HB-EGF) for EGFR have 
been found, a ligand for ErbB2 has not been identified. The ligands for ErbB3 and 
ErbB4 are the neuregulins (NRG). Stimulation with EGF or NRG induces either 
homo- or hetero-dimerization of different pairs of members of the EGFR family. 
ErbB2 may function as a heterodimeric partner with the other members of the family, 
and hence, be activated by ligands that recognize the dimerization partner. 
Activation of the EGFR family RTKs leads to activation of multiple downstream 
signaling pathways, including the Ras-Raf-MEK-ERK MAPK pathway, the PI3K-Akt 
pathway, and the signal transduction and activator of transcription (STAT) pathway. 
EGFRs are deregulated in cancer cells in several ways. First, EGFRs can be 
deregulated by overexpression of EGFRs or their ligands. EGFRs overexpression by 
gene amplication has been found in many different human cancers, including breast 
and lung carcinomas (20). Second, EGFRs can be deregulated by activating 
mutations. Recently, somatic mutations that increase the sensitivity of the receptor 
to its ligand and alter receptor signaling were identified in the EGFR tyrosine kinase 
domain in subgroup of patients with non–small-cell lung cancer (NSCLC) (21, 22).  
EGFRs can be inhibited pharmacologically by multiple mechanisms (23). First, 
catalytic activity of the EGFRs can be inhibited by small molecules blocking the ATP 
binding site of the receptor. Gefitinib (Iressa) and erlotinib (Tarceva) are EGFR-
specific small molecule tyrosine kinase inhibitors (TKIs) and approved by the Food 
and Drug Administration (FDA) for the treatment of advanced and metastatic 
NSCLCs. Second, EGFRs can be inactivated by neutralizing antibodies against 
EGFR or their ligands. Examples include trastuzumab (Herceptin), a recombinant 
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humanized monoclonal antibody against ErbB2, and cetuximab (Erbitux), a chimeric 
antibody against EGFR (23).  
In addition to the EGFR family of RTKs, there are several other RTKs 
implicated in cancer (5). The MET RTK has been found to be overexpressed in 
melanoma and musculoskeletal tumors, and activated by point mutations in NSCLC 
and renal carcinoma. Activating point mutations and fusions of the Ret/glial-derived 
neurotrophic factor receptor (GDNFR) occur in multiple endocrine neoplasia and 
thyroid carcinoma. Vascular endothelial growth factor (VEGF) and its RTKs 
(VEGFR-1 and VEGFR-2) have been found to be overexpressed in many cancers, 
including NSCLCs, breast, prostate, and colorectal cancers. Bevacizumab (Avastin), 
a recombinant humanized anti-VEGF monoclonal antibody, has been shown to 
significantly improve survival rate when used in combination with standard first-line 
chemotherapy in patients with advanced NSCLC. Several small molecule VEGFR 
inhibitors have also shown promise in clinical trials in NSCLC (24).  
II. FGFR family of RTK 
A. Identification of FGFs 
Fibroblast growth factors (FGFs) are a large family of growth factors that 
mediate a variety of cellular responses including cell proliferation, differentiation, 
migration, and angiogenesis (1, 2). The activities of FGFs are mediated by binding to 
FGFRs, a family of receptor tyrosine kinases (RTKs), with heparan sulfate 
proteoglycan as a cofactor. To date, 22 Fgf genes have been found in humans. The 
first FGF was isolated from bovine pituitary gland as a mitogen that could stimulate 
the growth of fibroblast cell lines. It was termed basic FGF (bFGF/FGF2) based on 
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its high isoelectric point (25). A second FGF was subsequently isolated from brain 
extracts and termed acidic FGF (aFGF/FGF1) based on its lower isoelectric point 
when compared to bFGF (26). Since then, at least 22 members of the mammalian 
FGF have been identified. FGF3 (INT-2) (27), FGF4 (28) and FGF5 (29) were 
originally identified as oncogenes, while FGF6 was identified based on sequence 
homology to FGF4 (30). FGF7 (keratinocyte growth factor; KGF) was identified as 
an epithelial-specific mitogen from conditioned medium of a human embryonic lung 
fibroblasts (31, 32). Unlike FGF1 and FGF2, FGF7/KGF is mitogenic for 
keratinocytes but not for fibroblasts or endothelial cells. FGF8 was purified as an 
androgen-induced growth factor from the conditioned medium of mouse mammary 
carcinoma cells (33) and FGF9 was identified as glial activating factor that stimulate 
growth of glial cells (34). FGF10 was initially identified from rat embryos by 
homology based PCR (35). FGF10 protein sequence is similar to FGF7. Like FGF7, 
FGF10 is expressed in stromal cells and mitogenic to keratinocytes. The remaining 
FGFs were identified based on sequence information rather than the isolation of 
growth-promoting factor from tissue or cell llines (3).   
 
B. Structural diversity of FGFRs   
To date, four FGFR genes have been found in humans. Like other RTKs, all 
four FGFRs (FGFR1–4) are comprised of an extracellular ligand-binding domain, a 
single transmembrane domain and a cytoplasmic domain with tyrosine kinase 
activity and additional regulatory sequences in carboxyl-terminus (Fig. 1-2). The 
extracellular ligand-binding domain of FGFR consists of a signal peptide,  three 
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immunoglobulin (Ig) like domains (designated as IgI, IgII and IgIII domains; also 
called D1-D3) as well as a cluster of acidic and serine/threonine amino acids known 
as the “acid box”  between the IgI and IgII domains (1, 3) (Figs.1-2 and 1-5). 
 In addition to multiple ligands and receptors, the complexity of FGF signaling 
is further diversified by the fact that the FGFR genes encode multiple structural 
variants that are generated by alternative gene splicing that occurs both in the 
extracellular and intracellular regions of the FGFRs (1, 3).  Thus, a single FGFR 
gene can encode multiple, functionally distinct receptors that differ in ligand binding 
specificity and cytoplasmic signaling activity.  In FGFR1-3, a major splicing event 
involves the exon encoding the Ig-I domain and determines whether the IgI domain 
is included in the mature receptors. FGFR splicing variants lacking the IgI domain 
are still able to bind to ligands and biologically functional, indicating that IgI domain 
is not critical for FGF binding and FGFR function. A second alternative splicing event 
occurs in the IgIII domain of FGFR1-3 by using two alternative exons (IIIb and IIIc) 
encoding the carboxyl terminal half of the IgIII domain and the common exon IIIa 
(encoding the amino terminal half of the Ig-III domain) in a mutually exclusive 
fashion (Fig. 1-5). These alternative splicing events occur in a tissue-specific manner, 
resulting in either mesenchymal cell-specific “IIIc” or epithelial cell-specific “IIIb” 
isoforms.  In addition, alternative splicing of the sequences that encode the IgIII 
domain determines the ligand binding specificity of FGFRs. Table 1 summarizes the 
binding specificity of FGFR isoforms to different FGF ligands. The FGFR4 gene is 
unique in that there is no variant that differ in Ig-III domain of FGFR4.   Of the four 
FGFRs, the best characterized is FGFR1.  Since the focus of my dissertation 
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research has been FGFR2, for the remaining introduction I have concentrated on 
FGFR2. 
C. Alternative gene splicing of FGFR2: generation of functionally-distinct 
proteins from a single gene 
The typical example of splicing variation in IgIII domain is the IIIb and IIIc 
isoforms of FGFR2. The mesenchymal specific FGFR2 IIIc (also called bacterial 
expressed kinase; BEK) was isolated originally by the screening of a mouse liver 
expression cDNA library in λgt11 with antiphosphotyrosine antibodies (36, 37). 
Subsequently, the epithelial cell-specific FGFR2 IIIb was isolated in an expression 
library biological screen using FGF7/KGF-expressing NIH 3T3 mouse fibroblasts.  
FGFR2 IIIb was isolated originally from the transformed foci of NIH 3T3 fibroblasts 
that were transfected with a keratinocyte expression cDNA library (38). The two 
alternative IgIII splicing variants of FGFR2 show different ligand binding 
characteristics. While FGFR2 IIIb binds FGF7/KGF and FGF10, but not FGF2, 
FGFR2 IIIc binds FGF2, but not FGF7 and FGF10 (Fig. 1-5). Whereas most FGFs 
bind more than one FGFR isoforms (Table 1), FGF7/KGF is unique among FGFs in 
that it binds exclusively to FGFR2 IIIb. Importantly, the tissue expression patterns of 
the ligands are generally opposite to the expression distribution of their receptors, 
resulting in the creation of paracrine signaling loops facilitated by epithelial and 
mesenchymal cell interactions during normal development (Fig 1-6).  
Another important FGFR2 splicing event occurs in sequences that encode the 
carboxyl-terminal cytoplasmic domain of FGFR2. To date, at least three splice 
variants of FGFR2 IIIb that differ in their carboxyl-terminal sequences have been 
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identified (designated C1, C2 and C3) (39). The C1 and C2 variants are generated 
from the same exon with two different splice acceptor sites, while the C3 variants are 
generated from a separate exon (Fig.1-7). The C2-type carboxyl-terminus is 34 
amino acids shorter than the C1-type carboxyl-terminus and C3-type carboxyl-
terminus is 19 amino acids shorter than C2-type carboxyl-terminus. These sequence 
differences result in differential retention of five tyrosine residues that may serve as 
sites of receptor autophosphorylation and docking sites for cytoplasmic signaling 
proteins (Fig. 1-8).  One previous study found that expression of the C3 isoform was 
increased in gastric cancer cell lines, suggesting that aberrant expression of the C3 
splicing variant may contribute to cancer development (39). Furthermore, the C3 
variant that lacks carboxyl-terminal sequences was shown to be more transforming 
than C1 variant in NIH 3T3 fibroblasts (39) and human mammary epithelial cells (40). 
Using a retrovirus-based cDNA expression library, derived from mRNA isolated from 
the T-47D human breast carcinoma cell line, our laboratory isolated the wild type 
sequences for the FGFR2 IIIb C2 isoform. Since little has been done to characterize 
the signaling and biological activity of this isoform, I chose to study this unique 
FGFR2 isoform to evaluate and establish its role in breast cancer growth.  To date, 
the majority of studies evaluating FGFR2 IIIb function have been done in fibroblast 
cells.  Since FGFR2 IIIb proteins are normally epithelial cell-restricted in expression, 
and upregulated in cancers that arise from epithelial cells, studies of FGFR2 IIIb 
function in epithelial cells will provide a more physiologically-relevant approach.  
Furthermore, the studies in fibroblasts are complicated by the fact that fibroblasts 
express the ligands for FGFR2 IIIb.  In chapter two, I summarize my studies 
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Figure 1-5. Alternative splicing of FGFR2 and differential ligand stimulation.  
Alternative splicing occurs in IgIII domain of FGFR2 by using two alternative exons 
(IIIb and IIIc) encoding the carboxyl terminal half of the Ig III domain and the 
common exon IIIa (encoding the amino terminal half of the Ig-III domain) in a 
mutually exclusive fashion.  
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Figure 1-6. FGFR2 IIIb and KGF create a paracrine signaling loop between 
epithelial and mesenchymal cells.  
The epithelial cell specific FGFR2 IIIb is stimulated by KGF that is secreted by 
mesenchymal cells, resulting in the formation of paracrine signaling loop. KGF does 
not bind to the mesenchymal specific FGFR2 IIIc.  
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evaluating the transforming and signaling activities of FGFR2 IIIb C2 in epithelial 
cells. 
D.  FGFR signaling    
Like other RTKs, upon ligand binding, FGFRs dimerize and result in 
autophosphorylation on several tyrosine residues in their carboxyl terminal 
sequences. The docking proteins that recognize the carboxyl terminal sequences of 
FGFRs, and the signaling pathways that they regulate, have been best-
characterized with FGFR1.  Then, phosphorylated tyrosine residues recruit other 
signaling molecules to the activated FGFRs. One key signaling molecule recruited to 
activated FGFRs is phospholipase C gamma (PLCγ).  Another important signaling 
molecule, FRS2 (FGF receptor substrate 2), is bound persistently to inactive FGFR.  
However, upon ligand binding, FRS2 is phosphorylated and activated by the 
activated FGFR (1, 6) (Fig.1-9) FRS2 is a docking protein and two members of the 
FRS2 family have been identified. FRS2α and FRS2β are structurally similar, and 
both of them contain myristyl. anchors and PTB domains in their amino-termini and 
multiple tyrosine phosphorylation sites in their carboxyl-termini (41). FRS2α contains 
binding sites for the adaptor protein Grb2 (41) as well as protein tyrosine 
phosphatase Shp2 (42). Activation of FGFRs lead to tyrosine phosphorylation of 
FRS2α, and the tyrosine phosphorylated FRS2α provides binding sites for the SH2 
domains of Grb2 and Shp2. Once associated with FRS2α, Shp2 is tyrosine 
phosphorylated and recruits Grb2 indirectly to the FRS2α. Then, Grb2 forms a 
complex with Sos via its SH3 domain and this complex formation allows Sos to 
translocate to the plasma membrane where it can stimulate Ras activation, leading 
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Figure 1-7. Alternative splicing of FGFR2 IIIb and carboxyl-terminal sequence 
variation.  
The C1 and C2 variants are generated from the same exon with two different splice 
acceptor sites, while the C3 variants are generated from a separate exon. The C2-
type carboxyl-terminus is 34 amino-acid shorter than the C1-type carboxyl-terminus 
and C3-type carboxyl-terminus is 19 amino-acid shorter than C2-type carboxyl-
terminus.  
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Figure 1-8. FGFR carboxyl terminal sequences. 
 (A)  Carboxyl terminal variants of FGFR2 encoded by alternative splice variants of 
FGFR2.  (B) Conservation of tyrosine residues in FGFR carboxyl terminal 
sequences.  
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to activation of the ERK MAPK and other Ras effector signaling pathways. In 
addition, Grb2 can recruit the docking protein Gab1, which is then tyrosine 
phosphorylated by FGFR activation (43). The tyrosine phosphorylated Gab1 recruits 
SH2 domain-containing signaling molecules, in particular PI3K, resulting in activation 
of the PI3K-AKT cell survival pathway (Fig 1-8).  In Chapter two, I described my 
studies evaluating the importance of FRS2 adaptor function in FGFR2-mediated 
growth transformation. 
FGFR signaling also activates phosphatidylinositol (PI) hydrolysis. In FGFR1, 
autophosphorylation on Y766 in the carboxyl-terminus serves as a binding site for 
the SH2 domain of PLCγ, resulting in tyrosine phosphorylation of PLCγ (44, 45) (Fig. 
1-10). Phosphorylation and activation of PLCγ leads to stimulation of PI hydrolysis 
and the generation of the two second messengers, diacylglycerol and Ins(1,4,5)P3. 
These two second messengers cause the activation of protein kinase C and the 
Ca2+ release from intracellular stores, respectively (46) (Fig.1-9). The Y766 residue 
in FGFR1 is well conserved in all four FGFR family members (Fig. 1-8). Recently, it 
was shown that mutant FGFR2 IIIb in which Y770 is replaced with phenylalanine 
cannot bind and phosphorylate PLCγ, whereas it was not determined whether this 
mutant fails to activate PI hydrolysis (47). My studies in Chapter Three evaluated the 
role of FGFR2 activation of PLCγ in FGFR2-mediated growth transformation. 
E. FGFR mutations in human skeletal disorders  
Activating mutations in FGFR1-3 gene have been associated with several 
skeletal disorders, including chondrodysplasia syndromes (dwarfism) and 
craniosynostosis syndromes (premature fusion of the cranial sutures) (48, 49). 
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Craniosynostosis syndromes are mostly caused by gain-of-function mutations in 
FGFR2 and include the Pfeifer, Crouzon and Apert syndromes (Fig.1-11). One class 
of mutations causing Pfeifer and Crouzon syndromes involves the loss a cysteine 
(for example, C278F and C342R) or gain of a cysteine (for example, W290C and 
S351C). The consequence of this class of mutations is to generate odd numbers of 
cysteine residues in the IgIII domain that facilitates the formation of intermolecular 
disulfide bonds causing ligand-independent dimerization. Another class of mutations 
causing Apert syndrome involves a missense mutation in one of two missense 
mutations (S252W or P253R) in the linker region between the IgII and IgIII domains 
of FGFR2 that is involved in ligand binding. It was demonstrated that these 
mutations in FGFR2 allow the mesenchymally-expressed mutant FGFR2 IIIc to be 
activated by mesenchymal cell expressed ligands such as FGF7 and FGF10 and the  
epithelial cell expressed mutant FGFR2b to be activated by epithelial cell expressed 
ligands such as FGF2, 6, and 9, resulting in the creation of aberrant autocrine 
growth signaling loop (50, 51). 
F. FGFRs and cancer 
 
FGFRs have been implicated in cancer by several mechanisms including 
activating mutations and chromosomal translocations. First, the activating FGFRs 
mutations involved in developmental defects have been also found in cancer 
patients. For example, somatic activating mutations of FGFR3 in bladder and 
cervical carcinomas were found at identical positions (R248C, S249C, G372C and 
K652E), where germline mutations of FGFR3 causing dwarfism also occur (52). In 
addition, activating FGFR2 somatic mutations (for example, S267P and S252W) that  
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Figure 1-9. FGFR cytoplasmic signaling.   
Activation of FGFRs leads to tyrosine phosphorylation of FRS2, and the 
phosphorylated FRS2α provides binding sites for the SH2 domains of Grb2 and 
Shp2. Tyrosine phosphorylated Shp2 can recruit Grb2 indirectly to associate with 
FRS2. Then, Grb2 forms a complex with Sos via its SH3 domain. In addition, Grb2 
can recruit the docking protein Gab1, which is subsequently tyrosine phosphorylated 
and causes activation of the PI3K-Akt pathway. In FGFR2, autophosphorylation of 
Y770 in carboxyl-terminus serves as a binding site for the SH2 domain of PLCγ, 
resulting in tyrosine phosphorylation and activation of PLCγ. 
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Figure 1-10. Possible roles for Y770 in FGFR2 function.  
(A) Second messenger signaling.  (B) Receptor internalization and degradation. 
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Figure 1-11. FGFR2 mutations in craniosynostosis syndromes and cancer. 
Craniosynostosis syndromes  are characterized by premature fusion of the cranial 
sutures and include the Pfeifer, Crouzon and Apert syndromes. Interestingly, 
activating somatic mutations of FGFR2 identical to germ line mutations in 
craniosynostosis syndromes (for example, S252W and W290C, indicated as red) 
were also identified in gastric, endometrial and lung carcinomas.  
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Figure 1-12. FGFR1 chromosomal translocation in myeloproliferative 
syndrome (EMS).  
The most common chromosomal translocation in EMS is t(8;13)(p11;q12) and 
generates a ZNF198-FGFR1 fusion protein that contains the zinc finger motif and 
proline-rich domain of ZNF198 and the intracellular tyrosine kinase domain of 
FGFR1. The zinc finger motif and proline-rich domains in amino-terminus of 
ZNF198-FGFR1 facilitate the dimerization of the fusion protein, resulting in the 
creation of a constitutively activated tyrosine kinase.  
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are identical to the germ line mutations associated with craniosynostosis syndromes 
(Fig.1-11) were identified in gastric and endometrial carcinomas (53, 54). Moreover, 
systemic analyses of somatic mutations in human cancer genomes identified 
somatic mutations of FGFR1 and FGFR2 in lung cancers at identical positions 
(P252T in FGFR1 and W290C in FGFR2) where germ line mutations that cause 
Pfeifer syndrome occurs (55, 56).  Chromosomal translocations often result in the 
creation of tumor-specific fusion proteins. These fusion proteins are considered to 
play an important role in the development of hematological malignancies. 
Translocation and fusion between FGFR1 and at least four alternative partner genes 
have been identified in 8P11 myeloproliferative syndrome (EMS). The most common 
chromosomal translocation in EMS is t(8;13)(p11;q12) and generates ZNF198-
FGFR1 fusion protein that contains the zinc finger motif and proline-rich domain of 
ZNF198 and the intracellular tyrosine kinase domain of FGFR1 (57). The zinc finger 
motif and proline-rich domains in amino-terminus of ZNF198-FGFR1 facilitate the 
dimerization of fusion protein, resulting in the creation of a constitutively 
activatedtyrosine kinase (Fig.1-12).  Subsequently, other FGFR1 fusion partner 
genes, including FOP (58), CEP110 (59) and BCR (60), have been identified. Like 
ZNF198-FGFR1, all these fusion proteins contain non-FGFR1 dimerization domains 
that are fused to the tyrosine kinase domain of FGFR1, resulting in constitutive 
activation of FGFR1 kinase activity. A constitutively active form of FGFR2 fusion 
protein was identified in rat osteosarcoma (ROS) cells (termed as FGFR2-ROS) (61). 
The FGFR2-ROS contains an altered carboxyl terminus generated from 
chromosomal rearrangement with a novel gene, designated FGFR activating gene 1 
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(FRAG1). The FGFR2-ROS fusion protein appears to form constitutive dimmers, 
resulting in constitutively activated tyrosine kinase. Fusion of the ETV6/TEL gene to 
FGFR3 was found in a patient with peripheral T-cell lymphoma (PTCL) with a 
t(4;12)(p16;p13) translocation (62). The TEL-FGFR3 fusion protein consists of the 
HLH domain of ETV6/TEL in amino-terminus and the tyrosine kinase domain of 
FGFR3 in carboxyl-terminus. TEL-FGFR3 fusion protein displays constitutive kinase 
activity that is mediated by the oligomerization of the HLH domain (63).   
A third mechanism by with FGFR function can be deregulated in human 
cancers involves changes in gene splicing and the preferential expression of 
functionally-distinct forms of FGFR2 in cancers.  In my studies in Chapter Two, I 
describe my studies suggesting that differential gene splicing and expression of the 
C2 and C3 isoforms of FGFR2 IIIb results in preferential expression of transforming 
variants of this receptor.  Additionally, I describe a shift in gene splicing in invasive 
breast cancers that favors expression of the normally mesenchymal-restricted 
FGFR2 IIIc isoform.  This isoform may then promote EMT and breast cancer 
progression. 
 
III. FGFR2 and oncogenesis 
A. Opposing roles for FGFR2 in oncogenesis 
Although the role of FGFR2 IIIb in organ development has been well studied, 
much less is known regarding the role of FGFR2 IIIb in oncogenesis. In particular, 
there are conflicting observations for the role of FGFR2 IIIb in oncogenesis. While 
some reports demonstrated that FGFR2 IIIb is a transforming oncoprotein, other 
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reports showed that FGFR2 IIIb functions as a tumor suppressor. For example, 
ectopic expression of FGFR2 IIIb in human prostate tumor PC-3 cell lines (64) or 
salivary adenocarcinoma cells (65) resulted in reduced cell growth. Furthermore, 
expression of FGFR2 IIIb was shown to be downregulated in bladder carcinomas 
(66) and restoration of FGFR2 IIIb in human bladder carcinoma cells that lack 
FGFR2 IIIb caused reduced cell growth (67). In contrast, there are evidences 
suggesting that FGFR2 IIIb is an oncoprotein. FGFR2 IIIb was shown to be 
overexpressed in poorly differentiated types of stomach cancers and expression of 
FGFR2 IIIb caused transformation of NIH 3T3 fibroblasts (39). Moreover, it was 
shown that the Fgfr2 IIIb gene was amplified in the SUM-52PE breast cancer cell 
line and ectopic expression of FGFR2 IIIb in the immortalized human mammary 
epithelial cell line H16N2 induced growth transformation (40, 68). The basis for the 
seemingly opposing roles of FGFR2 IIIb in cellular transformation and oncogenesis 
is not known, and may reflect cellular genetic context differences in FGFR2 function.  
That such opposing functions can be ascribed to a single signaling protein is not 
surprising and has been seen for other oncoproteins, such as Ras, and are 
discussed in the next section.  
 
B. Cell type-specific differences in transformation.   
The accumulated evidences indicate that cell type-specific differences exist in 
cellular transformation and oncogenesis.  For example, transforming growth factor β 
(TGF-β) inhibits the growth of epithelial cells, whereas TGF-β can induce oncogenic 
transformation of fibroblasts (69, 70). Furthermore, we and others have previously 
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found that although activating Ras or Raf transforms rodent fibroblasts, only Ras but 
not Raf transforms epithelial cells (71, 72), suggesting distinct mechanisms exist for 
Ras transformation in epithelial cells and fibroblasts. Although previous studies 
showed FGFR2 IIIb transformed both fibroblasts and epithelial cells (38-40), whether 
FGFR2 IIIb causes transformation of fibroblasts and epithelial cells by distinct or 
common, mechanisms has not been determined.  
 
C. Potential role of FGFR2 in epithelial to mesenchymal transition (EMT) 
and cancer development 
EMT is a fundamental process for morphogenesis during embryonic 
development and is also implicated in the carcinoma progression (73-75). EMT is 
characterized by the loss of cell polarity and cell-cell contacts, gain of fibroblastic 
morphology, and loss of epithelial (E-cadherin, β-catenin) and gain of mesenchymal 
(N-cadherin, vimentin and fibronectin) marker expression (Fig. 1-13). Several 
developmentally important genes that induce EMT during embryonic morphogenesis 
have been also implicated in tumor progression.  For example, Snail and the closely 
related gene Slug, which are essential for gastrulation during embryonic 
development, have shown to be transcriptional repressors of E-cadherin and 
mediators of EMT in human invasive carcinoma cells (76-78).  More recently, Twist, 
a key regulator of embryonic morphogenesis, was found to play an essential role in 
breast cancer metastasis by loss of E-cadherin-mediated cell-cell adhesion, 
activation of mesenchymal markers, and induction of cell motility (79). Several 
growth factors, including TGFβ, HGF/SF (hepatocyte growth factor/scatter factor), 
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FGF, and EGF have been shown to induce EMT by activating Ras and ERK MAPK 
pathway or the PI3K-Akt pathway in certain epithelial cells (78, 80, 81) (Fig.1-11).  
There is evidence that FGFR2 IIIb signaling may induce EMT. Thiery and 
colleagues showed that FGF1 or FGF7, but not FGF2 can induce EMT in NBT-II rat 
bladder carcinoma cells that express FGFR2 IIIb, but not FGFR1 or FGFR2 IIIc (81). 
They also showed that treatment of FGF1 induced an FGFR2 IIIb to FGFR2 IIIc 
exon switch in NBT-II cells. Interestingly, this exon IIIb to IIIc splicing switch is 
accompanied by a gain of a fibroblastic morphology and enhanced cell motility. A 
loss of FGFR2 IIIb expression and gain of FGFR2 IIIc expression was also observed 
in rat prostate tumor progression model and prostate cancer cells (82, 83). Taken 
together, these observations suggest that aberrant expression of mesenchymal 
specific FGFR2 IIIc in epithelial cells might contribute to cancer progression by 
inducing EMT. However, the possible role of FGFR2 IIIc in cancer progression has 
not been explored.  In my studies in Chapter two, I explored the possible role of 
alternative gene splicing and expression of the normally mesenchymal cell-restricted 
FGFR2 IIIc isoform in invasive breast cancers as a mediator and/or marker of EMT. 
In summary, despite the strong evidence that aberrant FGFR function may 
promote oncogenesis, the role of gene splice and the specific involvement of FGFR-
mediated signaling in cancer development and growth are areas that remain poorly 
understood.  In Chapter Two, I explore cell context differences in FGFR2 
transforming activity and the role of alternative splice in altering FGFR2 biological 
function in breast cancer growth and invasion, as well as EMT.  In Chapter Three, I 
evaluate the mechanistic consequences of alternative gene splicing and loss of 
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carboxyl terminal sequences in activating FGFR2 transforming activity.  In particular, 
these studies critically evaluate the key cytoplasmic signaling events that may 
promote FGFR2 growth transformation and implicate aberrant receptor endocytosis 
as an important mechanism for FGFR2 activation in cancer.  My studies establish 
gene splicing as an important mechanism of FGFR2 activation in cancer, and they 
further validate FGFR2 as an oncogene that promotes epithelial cell transformation. 
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Figure 1-13. Regulators of EMT. 
E-cadherin repressors such as Snail and Twist induce EMT, which is characterized 
by a loss of cell-cell contacts, a gain of fibroblastic morphology, and a loss of 
expression of epithelial and gain of expression of mesenchymal markers. Growth 
factor receptor mediated Ras activation or TGFβ/smad pathways induce EMT by 
increasing Snail expression. Snail and Twist induce EMT by downregulating E-
cadherin expression.  
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Chapter 2: Cell Context-dependent Mechanisms of FGFR2 IIIb 
Transformation of Fibroblast and Epithelial Cells 
 
I. Abstract 
We identified the IIIb C2 epithelial cell-specific splice variant of fibroblast growth 
factor receptor 2 (FGFR2 IIIb C2) receptor tyrosine kinase in a screen for activated 
oncogenes expressed in T-47D human breast carcinoma cells.  We found FGFR2 
IIIb C2 expression in breast carcinoma cell lines and additionally, expression of the 
mesenchymal-specific FGFR2 IIIc splice variant in invasive breast carcinomas. 
Furthermore, we found FGFR2 IIIc expression was associated with loss of epithelial 
and gain of mesenchymal markers. Although FGFR2 IIIb is expressed in epithelial 
cells, previous studies on FGFR2 IIIb transformation have focused on fibroblasts. 
Since cell-type specific differences exist in cellular transformation and oncogenesis, 
we compared the transforming activities of FGFR2 IIIb C2 in NIH 3T3 fibroblasts and 
RIE-1 intestinal epithelial cells.  FGFR2 IIIb C2 caused growth transformation of both 
cell types but morphologic transformation of only NIH 3T3 cells. FGFR2 IIIb C2-
transformed NIH 3T3 but not RIE-1 cells showed persistent activation of Ras and 
increased cyclin D1 protein expression.  NIH 3T3, but not RIE-1, cells express 
keratinocyte growth factor (KGF), a ligand for FGFR2 IIIb C2. Ectopic treatment with 
KGF caused FGFR2 IIIb C2-dependent morphologic transformation of RIE-1 cells, 
as well as cyclin D1 upregulation, indicating that both ligand-independent and 
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stromal cell derived ligand-dependent mechanisms contribute to epithelial cell 
transformation.  FGFR2 IIIb C2 transformation of RIE-1 cells was also dependent on 
an epidermal growth factor receptor autocrine mechanism.  Our results support 
distinct mechanisms of FGFR2 IIIb C2 transformation of fibroblast and epithelial cells.  
II. Introduction 
Fibroblast growth factors (FGFs) comprise a large family of structurally related 
growth factors (22 human members) that mediate a variety of cellular responses that 
include cell proliferation, differentiation, migration, and angiogenesis (1, 2, 84).  The 
activities of FGFs are mediated by their binding to a family of four receptor tyrosine 
kinases (RTKs), designated FGFR1-4.  FGFRs are comprised of an extracellular 
domain that consists of two or three immunoglobulin (Ig)-like domains, a single 
transmembrane domain and an intracellular catalytic tyrosine kinase domain and 
flanking regulatory sequences (Fig. 1A).  
In addition to multiple ligands and receptors, the complexity of FGF signaling 
is further diversified by the fact that the FGFR genes encode multiple structural 
variants that are generated by alternative gene splicing (1, 2, 84).   Most importantly, 
in the case of FGFR1-3, alternative RNA splicing and exon utilization of sequences 
encoding the carboxyl-terminal half of the third Ig-like domain III results in the 
expression of either the IIIb or IIIc isoform of the FGFRs (Fig. 1A). This alternative 
splicing occurs in a tissue-specific manner and determines the ligand binding 
specificity of FGFRs. For example, FGFR2 IIIb (also called KGFR and K-sam-II) 
binds FGF7 (also called keratinocyte growth factor; KGF) and FGF10, but not FGF2, 
whereas the FGFR2 IIIc (also called Bek/K-sam-I) binds FGF2 and FGF18, but not 
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FGF7 and FGF10. Additionally, ligand and receptor expression can be tissue 
restricted and expressed in a non-overlapping tissue distribution.  FGFR2 IIIb 
expression is restricted exclusively to normal epithelial cells, while FGFR2 IIIc 
isoform is generally expressed in normal mesenchymal cells. In contrast, expression 
of the ligands for FGFR2 IIIb (KGF/FGF7 and FGF10) is restricted to mesenchymal 
cells, and ligands for the mesenchymal-restricted receptor are generally expressed 
in epithelial cells, resulting in the creation of paracrine signaling loops facilitated by 
epithelial and mesenchymal cell interactions during normal development. However, 
exon switching and expression of FGFR2 IIIc has been described in epithelial cell 
tumor progression.  A loss of FGFR2 IIIb expression and gain of FGFR2 IIIc 
expression was observed in rat prostate tumor progression from androgen-
dependence to androgen-independence (83).  A similar exon switch has been 
described for NBT-II rat bladder carcinoma cells, where the onset of FGFR2 IIIc 
expression was correalted with epithelial-mesenchymal transition (EMT), a process 
associated with tumor progression and invasion (75). 
Alternative splicing also results in FGFR2 variation in carboxyl-terminal 
sequences.  To date, at least three carboxyl-terminal splice variants of FGFR2 IIIb 
have been identified, designated C1, C2 and C3 (39) (Fig. 1B). The C2-type 
carboxyl-terminus is 34 amino-acid shorter than the C1-type carboxyl terminus, 
whereas the C3-type carboxyl terminus is 53 amino-acid shorter than C1-type 
carboxyl terminus.  These sequence differences result in differential retention of 
tyrosine residues that may serve as sites of receptor autophosphorylation and 
docking sites for cytoplasmic signaling proteins.  Enhanced expression of the C3 
 38
isoform was seen in gastric cancer cell lines (39).  Ethier and colleagues found that 
normal human mammary epithelial cells express FGFR2 IIIb C1 and C2, but C3 
isoform expression found only in the SUM-52 breast tumor cell line (68).  Previous 
studies showed that FGFR2 IIIb C1 and IIIb C3 could promote growth transformation 
of NIH 3T3 mouse fibroblast (39) and H16N2 immortalized human mammary 
epithelial cells (40), with C3 exhibiting greater transforming activity.  However, the 
transforming activity of FGFR2 IIIb C2 has not been evaluated.   
 FGFRs are activated by ligand-induced dimerization, causing stimulation of 
their intrinsic tyrosine kinase activity, tyrosine autophophorylation, and recruitment of 
signaling proteins to specific phosphorylated tyrosine residues in their cytoplasmic 
carboxyl-termini (1).  FGFRs activate the FGFR substrate 2 (FRS2) docking proteins.  
FGFR phosphorylation of FRS2 creates phosphorylated tyrosine docking sites for 
the Grb2 adaptor protein.  Recruitment of Grb2 in complex with the SOS Ras-
specific guanine nucleotide exchange factor causes activation of Ras and the ERK 
mitogen-activated protein kinase (MAPK) cascade.  Ras can also activate the 
phosphatidylinositol 3-kinase (PI3K)-AKT serine/threonine kinase pathway in some 
cell types. FRS2-dependent FGFRs signaling can also activate the PI3K-AKT 
pathway through Grb2 and the Grb2-associated docking protein Gab1.  Since the 
majority of studies evaluating FGFR signaling are based on transient stimulation with 
FGFs that can activate multiple FGFRs (for example, FGF1 binds and stimulates all 
four FGFR1-4 isoforms), it is not clear whether the identified FGFR signaling 
activities described above are common for all four FGFRs.  Furthermore, the 
 39
majority of studies have focused on FGFR1 and there has been little effort made in 
studying the signaling activities that mediate FGFR2 IIIb oncogenesis.  
The accumulated evidences indicate that cell type-specific differences exist in 
cellular transformation.  For example, transforming growth factor β (TGF-β) inhibits 
the growth of epithelial cells, whereas TGF-β induces oncogenic transformation of 
fibroblasts (69, 70, 85).  Furthermore, we and others have previously found that 
although activating Ras or Raf transforms fibroblasts, only Ras but not Raf 
transforms epithelial cells, suggesting distinct mechanisms exist for Ras 
transformation in epithelial cells and fibroblasts (71, 72). The majority of studies 
have evaluated the transforming potential of FGFR2 IIIb in NIH 3T3 mouse 
fibroblasts (38, 39, 86).  Since fibroblasts and not epithelial cells express FGFR2 IIIb 
ligands, the biological analyses of FGFR2 IIIb in fibroblasts is complicated by an 
autocrine growth loop not present in epithelial cells.  Since FGFR2 IIIb is an 
epithelial cell-specific splice variant, an evaluation of FGFR2 IIIb signaling and 
biological activity in an epithelial cell model system may provide a more 
physiologically-relevant assessment of the role and mechanism of aberrant FGFR2 
IIIb function in human epithelial cell-derived carcinomas. Therefore, in the present 
study, we evaluated the transforming activities and signaling mechanisms of FGFR2 
IIIb in epithelial cells.  Since we identified the C2 isoform of FGFR2 IIIb in a screen 
for activated oncogenes, and determined that C2 expression was characteristic of 
the majority of breast carcinoma cells, we focused our analyses on this isoform.  We 
found that while FGFR2 IIIb C2 caused growth transformation of NIH 3T3 fibroblasts 
and RIE-1 epithelial cells, FGFR2 IIIb C2 transformation of RIE-1 cells was mediated 
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primarily by a ligand-independent mechanism that did not involve activation of Ras 
and Ras-mediated signaling.  Furthermore, FGFR2 IIIb C2 transformation of RIE-1 
cells was mediated, in part, by induction of an epidermal growth factor receptor-
dependent autocrine mechanism.  Finally, we found that expression of the 
mesenchyme-specific FGFR2 IIIc isoform in invasive breast carcinomas.  Taken 
together, our results suggest that FGFR2 IIIb causes growth transformation by 
distinct signaling mechanisms in fibroblast and epithelial cells, and that isoform 
switching might be a mechanism for FGFR2 deregulation in breast cancer 
progression. 
 
III. Materials and methods 
Cell Culture and Plasmid Expression Vectors 
NIH 3T3, RIE-1,  MCF-10A, NMuMG, and human breast carcinoma cell lines were 
maintained as we have described previously (72, 87).  Telomerase-immortalized 
human mammary epithelial cells (HMEC; provided by R. Weinberg, MIT) were 
maintained in MEGM growth medium (Clonetics).  The cDNA sequence encoding 
FGFR2 IIIb C2 was subcloned into the 5' blunt end and 3' SalI site of the pBabe-puro 
retroviral vector. The pCTV3 and pBabe-puro H-Ras(61L) expression vectors were 
described previously (88).  
Expression Library Screening
 Messenger RNA was purified from 2.8 x 107 T-47D cells and double stranded cDNA 
was synthesized and used to generate the cDNA library in the pCTV1B retroviral 
vector as described (89, 90). The T-47D cDNA plasmid library was then converted 
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into infectious retrovirus by transfection of 293T cells.  Rat-1 fibroblasts (5 x 105) and 
RIE-1 cells (7 x 105) were plated in 10 cm dishes (ten each) the day prior to infection 
with retrovirus expressing the T-47D cDNA expression library.  Genomic DNA was 
isolated from transformed foci and cDNAs were recovered by PCR as described (90). 
FGFR2 Isoform Expression Analyses 
To evaluate the expression of FGFR2 C1, C2 and C3 splicing variants in human 
breast cells, total cellular RNA was isolated from each cell line and reverse 
transcribed. The resulting cDNAs were amplified by PCR for 35 cycles. The primer 
sequences used for amplification of FGFR2 C1, C2 and C3 cDNA fragments were 
described previously (39). Our analysis of exon IIIb and IIIc expression was done as 
described previously (82), with PCR amplification of the cDNA sequences for 50 
cycles. 
Transformation Assays 
 For primary focus formation assays, NIH 3T3 fibroblasts were plated at 2 x 105 cells 
per 60 mm dish. The following day, cells were transiently transfected with the pBabe-
puro empty vector, or encoding H-Ras(61L) or FGFR2 IIIb C2. For secondary focus 
formation assays, RIE-1 cells and NIH 3T3 fibroblasts were stably infected with the 
pBabe-puro empty vector or encoding H-Ras(61L) or FGFR2 IIIb C2. After infection, 
cells were selected in growth medium supplemented with puromycin (2 µg/ml).  
Multiple drug-resistant colonies were pooled and replated into 60 mm dishes and 
maintained in growth medium for three weeks before the appearance of foci of 
transformed cells was photographed. To determine the growth rate on plastic and 
saturation density, mass populations of NIH 3T3 and RIE-1 cells stably expressing 
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FGFR2 IIIb C2 were plated at 5 x 104 cells per 60 mm dishes. Cells were then 
trypsinized and duplicate dishes were counted every three days for 12-15 days.   
Parallel cultures of NIH 3T3 and RIE-1 cells stably-infected with the empty pBabe-
puro vector, or encoding activated H-Ras(61L), were included for negative and 
positive controls, respectively. To determine the anchorage-independent growth, 
NIH 3T3 and RIE-1 cells stably expressing either empty vector or FGFR2 IIIb C2 
were suspended in 0.4% bacto-agar in growth medium at 5 x 104 cells per 60 mm 
dish. The single cell suspensions were layered on top of 0.6% bacto-agar in growth 
media. After 14-21 days, colonies were stained with 2 mg/ml MTT (tetrazolium salt 
3,[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and the average 
number of colonies on duplicate dishes was calculated. 
Signaling Analyses  
 To determine the level of Ras activation, we utilized a GST fusion protein containing 
the Ras-binding domain (RBD) of Raf-1 as we have described previously (91, 92). 
To determine ERK and AKT activation, cells were lysed and then analyzed for active 
ERK and AKT by immunoblot analyses with antibodies specifically detect 
phosporylated ERK and AKT (Cell Signaling Technology), respectively. The 
membranes were stripped and reprobed with antibodies for total ERK (Santa Cruz 
Biotechnology, sc93) and AKT (Cell Signaling Technology), respectively. To 
determine cyclin D1 protein expression levels, immunoblot analyses were performed 
with anti-cyclin D1 antibody (Santa Cruz Biotechnology). To determine Rb 
phosphorylation and inactivation, immunoblot analyses were performed with 
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antibody specific for the phosphorylated (Ser 780), inactivated form of Rb (Cell 
signaling technology).  
Conditional Media Assays 
RIE-1 cells stably expressing either empty vector or FGFR2 IIIb C2 were plated and 
cultured in growth medium. After 3 or 12 days after plating, conditioned media from 
either vector infected cells or FGFR2 IIIb C2 expressing cells were collected by 
passage through 0.45 µM filter and added onto subconfluent parental RIE-1 cells. 
Where indicated, the cells were pretreated with either the U0126 MEK inhibitor 
(Promega) or the gefitinib EGFR inhibitor (a gift from Dr. Shelley Earp, UNC-Chapel 
Hill). 
 
IV. Results 
A. Identification of the FGFR2 IIIb C2 Splice Variant as a Transforming Protein 
from T-47D Breast Carcinoma Cells. 
To identify novel oncogenes involved in breast epithelial cell growth 
transformation, we generated a retrovirus-based cDNA expression library from 
mRNA expressed in T-47D human breast carcinoma cells. The cDNA expression 
library was introduced into Rat-1 fibroblasts and RIE-1 epithelial cells.  One 2.3 kb 
cDNA sequence was identified independently as a sequence that induced focus 
formation in both our Rat-1 and RIE-1 screenings. This sequence encodes for 
FGFR2 IIIb C2, the epithelial cell-specific splice variant of FGFR2 (Fig. 2-1).  
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 Figure 2-1. Human FGFR2 isoforms. 
A. Structure of FGFR2 amino-terminal isoforms.  Cell type-specific alternative exon 
utilization and gene splicing results in formation of two amino-terminal variants, the 
epithelial cell-specific IIIb isoform and the mesenchymal-specific IIIc isoform.  
Abbreviations: Ig, immunoglobulin-like; TM, transmembrane; TK, tyrosine kinase 
domain. B. Carboxyl-terminal sequence comparison of FGFR2 IIIb splice variants.  
Carboxyl-terminal amino sequence comparison of FGFR2 IIIb C1, C2 and C3 splice 
variants. The known or putative tyrosine phosphorylation sites are bolded and 
indicated by their residue number.  FGFR2 IIIb C1 (822 aa), C2 (788 aa) and C3 
(769 aa) differ in the retention of these tyrosine residues as well as divergence in the 
underlined residues. 
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B. Aberrant Expression of the Mesenchymal FGFR2 IIIc Isoform in Invasive 
Breast Cancer Cell Lines.  
The SUM-52 breast cancer cell line expresses nine distinct FGFR2 IIIb 
isoforms that include the C1, C2 and C3 variants (68).  However, aside from this cell 
line, a systematic analysis of established breast carcinoma cell lines for FGFR2 IIIb 
isoform expression has not been done.  Therefore, we performed RT-PCR analyses 
to determine transcription of FGFR2 IIIb carboxyl-terminal isoforms in the 
immortalized, nontransformed MCF-10A human breast epithelial cell line and a 
panel of breast carcinoma cell lines.  We found that MCF-10A cells expressed 
predominantly C1, and very weakly, the C2 and C3 isoforms (Fig. 2-2A).  In contrast, 
the majority of tumor cell lines (6 of 9) showed significant expression of all three 
isoforms. 
To date, there has been limited analysis of the expression of the 
mesenchymal-specific FGFR2 IIIc in breast cancer cells.  Whereas exon switching 
and preferential expression of FGFR2 IIIc has been associated with tumor 
progression in two rat carcinoma models (75, 83), analyses of breast cancer tissue 
found exon switching to favor IIIc expression was associated with patients with 
advanced clinical staging (93).  Therefore, we utilized exon III-specific primers 
together with restriction enzyme analyses (82), to detect the expression of FGFR2 
IIIb and IIIc in breast carcinoma cell lines (Fig. 2-2B).  Since exon IIIb contains a 
unique AvaI site, whereas exon IIIc contains two HincII sites, digestion with these 
two enzymes allows detection of these two isoforms.  We found that FGFR2 IIIb 
expression was characteristic of untransformed MCF-10A and noninvasive (BT-474, 
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ZR-75-1, MCF-7, T-47D, MDA-MB-468, and SK-BR-3) breast cell lines, whereas 
FGFR2 IIIc was detected in all three invasive breast carcinoma cell lines (Hs578T, 
BT-549 and MDA-MB-231).  Previously, we verified that the Hs578T, BT-549 and 
MDA-MB-231, but not the untransformed MCF-10A or other carcinoma cell lines, 
showed invasive activity in vitro by using the Matrigel invasion and other assays (87). 
We also found that expression of FGFR2 IIIc was correlated with an epithelial-to-
mesenchymal transition (EMT), as indicated by the loss of epithelial (E-cadherin) 
and gain of mesenchymal (N-cadherin and vimentin) protein expression (Fig. 2-2B).  
Thus, breast cancer progression may involve two distinct alternative splicing events, 
with expression of FGFR2 IIIb C2/C3 isoforms associated with the progress from 
normal breast epithelia to non-invasive breast cancer, and the conversion to the 
mesenchymal FGFR2 IIIc isoform in invasive breast cancer cells. Previous studies 
have determined that FGFR2 IIIb C3 exhibits greater transforming activity than 
FGFR2 IIIb C1 (39, 40).  The transforming activity of the IIIb C2 isoform has not 
been evaluated.  Therefore, for the remainder of this study, we focused our analyses 
on the biological activity of the FGFR2 IIIb C2 isoform isolated in our transformation 
screen. 
  Our identification of FGFR2 IIIb C2 as a transforming protein in T-47D breast 
carcinoma cells suggests that FGFR2 IIIb C2 will function as an oncogene and 
promote breast epithelial cell growth transformation.  To address this possibility, we 
ectopically-expressed FGFR2 IIIb C2 in untransformed NMuMG mouse mammary 
epithelial cells, the spontaneously-immortalized, untransformed MCF-10A and 
telomerase-immortalized HMEC human breast epithelial cell lines.  All three cell 
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lines have been shown previously to be sensitive to activated Ras-mediated growth 
transformation (94-97).  Whereas empty-vector infected cells did not grow in soft 
agar, we found that FGFR2 IIIb C2-expressing NMuMG, MCF-10A and HMEC cells 
showed the ability to form colonies when suspended in soft agar (Fig. 2-2C and data 
not shown),  supporting an oncogene function for FGFR2 in T-47D breast carcinoma 
growth.  
 
C. Distinct Transforming Activities of FGFR2 IIIb C2 in NIH 3T3 Fibroblasts and 
RIE-1 Epithelial Cells.  
  Since previous studies evaluating FGFR2 IIIb function in NIH 3T3 mouse 
fibroblasts are complicated by fibroblast production of FGFR2 IIIb ligand, we focused 
our analyses using the RIE-1 cell line, a well-characterized rodent epithelial cell 
model system for the analyses of oncogene transformation.  Since previous studies 
used NIH 3T3 cells, we performed parallel analyses in NIH 3T3 cells to identify 
possible cell type differences in FGFR2 IIIb C2 transforming activity.  As 
expected from the identification of FGFR2 IIIb C2 in both our screens with Rat-1 and 
RIE-1 cells, we found that FGFR2 IIIb C2 caused potent formation of foci of 
transformed cells in NIH 3T3, RIE-1 and Rat-1 cells (Fig. 2-3A; data not shown).  
Formation of foci of transformed cells is indicative of a loss of density-dependent 
growth inhibition and/or morphologic transformation.  Therefore, we determined if 
FGFR2 IIIb C2 can cause these cellular parameters of oncogenesis.  First, we 
examined whether expression of FGFR2 IIIb C2 can cause loss of density–
dependent growth inhibition in NIH 3T3 fibroblasts and RIE-1 cells. Since FGFR2 IIIb 
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signaling can involve activation of Ras, we utilized activated H-Ras(61L) as a 
positive control for these analyses.  
  First, we found that expression of FGFR2 IIIb C2 induced primary focus 
formation in NIH 3T3 fibroblasts.  Next, we established RIE-1 cells stably infected 
with the pBabe-puro empty vector, or encoding FGFR2 IIIb C2 or activated H-
Ras(61L) (designated RIE(vector), RIE(FGFR2), RIE(Ras), respectively) and 
performed secondary focus formation assays. Whereas RIE(vector) cells showed no 
focus-forming activity, RIE(FGFR2) cells showed potent focus-forming activity (Fig. 
2-3A). Second, we determined whether FGFR2 IIIb C2 caused morphologic 
transformation of NIH 3T3 fibroblasts and RIE-1 cells. For these analyses, NIH 3T3 
fibroblasts were stably infected with the pBabe-puro empty vector, or encoding 
FGFR2 IIIb C2 or activated H-Ras(61L) (designated NIH(vector), NIH(FGFR2), 
NIH(Ras), respectively) . To our surprise, although FGFR2 IIIb C2 caused focus 
formation in both NIH 3T3 fibroblasts and RIE-1 cells (Fig. 2-3A), only NIH 3T3 
fibroblasts but not RIE-1 cells were morphologically transformed by FGFR2 IIIb C2 
(Fig. 2-3B). NIH(FGFR2) cells showed a highly retractile, elongated and spindle-
shaped cell morphology that was essentially identical to that of NIH(Ras) 
transformed cells. In contrast, the morphology of RIE(FGFR2) cells was 
indistinguishable from the RIE(vector) cells (Fig. 2-3B).  We next evaluated the 
growth rate and saturation density of NIH 3T3 fibroblasts and RIE-1 cells stably 
expressing FGFR2 IIIb C2.  When the cultures were at subconfluent densities 
(between day 0 and 6 post plating; Fig. 2-3C), NIH(FGFR2), but not RIE(FGFR2),  
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Figure 2-2. Expression of transcriptions encoding amino- and carboxyl-
terminal isoforms of FGFR2. 
A. Expression of FGFR2 C1, C2 and C3 variants in MCF-10A and human breast 
carcinoma cells. RT-PCR products were fractionated on an agarose gel and stained 
with ethidium bromide.  Matrigel (+) indicates that invasive or (-) non-invasive breast 
carcinoma cell lines as we have determined previously (87).  B. Expression of the 
mesenchyme-specific IIIc isoform in invasive breast carcinoma cell lines. RT-PCR 
products were obtained using FGFR2 exon III specific primers and digested with 
either AvaI or HincII (U=uncut, A=AvaI digest and H=HincII digest). Full length, uncut 
PCR products generate 367 bp and 364 bp bands for IIIb and IIIc isoforms, 
respectively. The presence of 249 bp and 118 bp bands following digestion with AvaI 
is indicative of FGFR2 IIIb. The presence of 125 bp, 120 bp and 119 bp bands 
following digestion with HincII is indicative of FGFR2 IIIc. Immunoblot analyses were 
done using antibody against E-cadherin, vimentin and N-cadherin for total cell 
lysates of the indicated cell lines.  C. FGFR2 IIIb induces anchorage-independent 
growth of NMuMG and MCF-10A cells. NMuMG and MCF-10A cells stably-
expressing either the empty vector or encoding FGFR2 IIIb C2 (designated FGFR2) 
were suspended in 0.4% soft agar and the number of proliferating colonies was 
quantitated after 3-4 weeks.  Data shown are the average of two dishes and 
representative of two or three independent assays. 
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cells displayed an increased growth rate when compared with their empty vector 
counterparts.   
However, at confluent densities (after day 6), both NIH(FGFR2) and 
RIE(FGFR2) cells showed increased growth rates when compared with NIH(vector) 
and RIE(vector) cells, respectively (Fig. 2-3C). In contrast, both NIH(Ras) and 
RIE(Ras) cells showed increased growth rates in both subconfluent and confluent 
cultures, indicating that FGFR2 IIIb C2, but not Ras, causes distinct growth 
promoting activities for fibroblasts and epithelial cells.  Finally, we assessed whether 
FGFR2 IIIb C2 can induce anchorage-independent growth of NIH 3T3 fibroblasts 
and RIE-1 cells and we found that both NIH(FGFR2) and RIE(FGFR2) cells, but not 
their empty vector counterparts, formed colonies in soft agar (Fig. 2-3D).  
 
D. FGFR2 IIIb C2 Causes Activation of Ras, ERK and AKT and Upregulation of 
Cyclin D1 Protein Levels in NIH 3T3 But Not RIE-1 Cells.  
  FGF stimulation activates multiple downstream signaling networks, including 
the Ras and ERK mitogen-activated protein kinase cascade (MAPK) (1). Surprisingly, 
little has been reported regarding whether FGFR2 IIIb is an activator of Ras and 
Ras-mediated signaling pathways.  Furthermore, most of studies done for FGFR2 
IIIb signaling have focused on transient activation of FGFR2 IIIb (47, 98-101) rather 
than sustained activation of FGFR2 IIIb in transformed cells. Therefore, we focused 
on characterizing the consequences of sustained activation of FGFR2 IIIb in stably-
transformed cells. First, we determined whether FGFR2 IIIb C2 caused sustained 
activation of Ras. To measure Ras activity, we performed a pull down assay utilizing 
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Figure 2-3. Distinct transforming activities of FGFR2 IIIb C2 in NIH 3T3 
fibroblasts and RIE-1 epithelial cells. 
A. FGFR2 IIIb C2 induces focus formation in NIH 3T3 and RIE-1 cells. NIH 3T3 cells 
were transfected with either the empty pBabe-puro vector (Vector) or encoding 
FGFR2 IIIb C2 (FGFR2) and the appearance of foci of transformed cells were 
photographed after 14 days in culture (left panel). RIE-1 cells were infected with the 
empty pCTV3 vector or encoding FGFR2 IIIb C2. Drug-resistant colonies were 
pooled and replated for secondary focus formation analyses. Cells were grown to 
confluence for 21 days before the appearance of foci of transformed cells was 
photographed (middle panel).  The cells were then fixed and stained with crystal 
violet (total dish; right panel).  B. FGFR2 IIIb C2 induces morphologic transformation 
of NIH 3T3 but not RIE-1 cells.  C. FGFR2 IIIb C2 shows distinct growth promoting 
activity in NIH 3T3 and RIE-1 cells dependent on cell density. D.  FGFR2 IIIb C2 
induces anchorage-independent growth of NIH 3T3 and RIE-1 cells.  
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a GST fusion protein containing the GTP-dependent Ras-binding domain from the 
Ras effector, the Raf-1 serine/threonine kinase (GST-Ras-RBD). As expected, the 
H-Ras-transformed NIH 3T3 and RIE-1 cells showed greatly elevated levels of Ras-
GTP.  Surprisingly, we found that NIH(FGFR2) but not RIE(FGFR2) cells showed an 
elevated level of activated GTP-bound Ras (Fig. 2-4A). 
 Next, we determined whether FGFR2 IIIb C2 caused sustained activation of 
downstream effector pathways of Ras. The two best-characterized effector pathways 
of Ras important for growth transformation are the Raf-MEK-ERK MAPK and the 
PI3K-AKT pathways. For these analyses, we utilized immunoblot analyses with 
phospho-specific antibody that recognizes the phosphorylated and activated forms 
of ERK1 and ERK2, or AKT.  As we have showed previously (102), activated Ras 
causes sustained ERK activation in NIH 3T3 and RIE-1 cells, and sustained AKT 
activation in NIH 3T3 but not RIE-1 cells (Fig. 2-4B). Expression of FGFR2 IIIb C2 
also led to sustained activation of ERK1/2 and AKT in NIH 3T3 fibroblasts, although 
the degree of activation was less than that seen in NIH(Ras) cells. In contrast, we 
found no increase in activated ERK or AKT levels in RIE(FGFR2) cells (Fig. 2-4B).  
Finally, we evaluated the consequences of FGFR2 IIIb C2 transformation on altered 
cell cycle regulation. Both the Raf-MEK-ERK and PI3K-AKT pathways have been 
shown to contribute to Ras-mediated upregulation of cyclin D1, a key positive 
regulator of cell cycle progression through G1 (103). Therefore, we examined 
whether FGFR2 IIIb C2 increased the steady-state levels of cyclin D1 protein. 
Consistent with the ERK and AKT activity levels, we found that cyclin D1 protein 
levels are upregulated in NIH(FGFR2) but not RIE(FGFR2) cells (Fig. 2-4B). These  
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Figure 2-4. FGFR2 IIIb C 2 activates Ras and Ras-mediated signaling in NIH 
3T3 but not RIE-1 cells. 
A. NIH 3T3 and RIE-1 cells stably expressing the indicated proteins were assayed 
for the amount of activated GTP-bound Ras by GST-Raf-RBD pull down analyses. 
GTP-bound and total Ras expression was determined by immunoblotting with anti-
pan-Ras antibodies.  B.  Ras signaling activation.  Cells were lysed and assayed for 
ERK and AKT activation by immunoblotting with antibodies that recognize 
phosphorylated ERK and AKT (designated P-ERK and P-AKT).  Same blots were 
reprobed with anti-ERK or anti-AKT antibodies to determine total ERK and AKT 
protein expression.  Cyclin D1 protein expression was determined by immunoblotting 
with cyclin D1 antibody. Data shown are representative of three independent 
experiments. 
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results suggest that FGFR2 IIIb C2 causes sustained activation of Ras and Ras-
mediated effector signaling in NIH 3T3 but not RIE-1 cells. 
 
E. MEK and PI3K Activities Are Required for FGFR2 IIIb C2-induced 
Anchorage-Independent Growth of RIE-1 Cells.   
  Although we found that FGFR2 IIIb C2 expression did not cause persistent 
activation of Ras-mediated signaling pathways in RIE-1 cells, it is possible that the 
basal activity of these signaling pathways might be necessary for FGFR2 IIIb C2 -
mediated growth transformation of RIE-1 cells. We found that treatment with either 
the U0126 MEK inhibitor or the LY294002 PI3K inhibitor blocked the anchorage-
independent growth of RIE(FGFR2) cells (Fig. 2-5A and B), indicating that both 
basal MEK and PI3K activities are required for FGFR2 IIIb C2-mediated 
transformation of RIE-1 cells. 
F. KGF Stimulates Morphologic Transformation and Increases Cyclin D1 
Protein Levels in FGFR2 IIIb C2-transformed RIE-1 Cells. 
  Since fibroblasts, but not epithelial cells, express the ligand (KGF/FGF7) for 
FGFR2 IIIb, it is expected that FGFR2 IIIb C2 will be stimulated by an autocrine 
mechanism in fibroblast but not epithelial cells. This may account for the absence of 
Ras activation that we observed in RIE(FGFR2) cells (Fig. 2-4). Thus, we postulated 
that exogenous ligand stimulation of RIE(FGFR2) cells should mimic the biological 
and signaling consequences of FGFR2 IIIb C2 seen in NIH(FGFR2) cells. We found 
that sustained KGF stimulation (for two days) caused morphologic transformation of 
RIE(FGFR2) but not control RIE(vector) cells (Fig. 2-6A), indicating that the 
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morphologic transformation seen with NIH(FGFR2) cells (Fig. 2-3B) is dependent on 
ligand stimulation of FGFR2 IIIb C2.   
 
 
 
 
 
 
 
 
 
Figure 2-5. MEK and PI3K activities are required for FGFR2 IIIb C2-induced 
anchorage-independent growth of RIE-1 cells. 
A. RIE-1 cells stably expressing empty vector or FGFR2 IIIb C2 were suspended in 
0.4% soft agar. The cells were incubated for three weeks in the absence or 
presence of 10 μM LY294002 (PI3K inhibitor) or 30 µM U0126 (MEK inhibitor). Cells 
were photographed about three weeks after plating.  B. Colonies per dish were 
counted two weeks after plating.  Data shown are the average of duplicate dishes, 
with the bars indicating standard deviation, and are representative of two 
independent experiments. 
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 The transformed morphology of KGF-stimulated RIE(FGFR2) cells (Fig. 2-6A) was 
similar to that seen with RIE(Ras) cells (Fig. 2-3B), with cells exhibiting a refractile, 
elongated and fibroblastic morphology.  This suggested that KGF stimulation may 
cause sustained Ras activation in RIE(FGFR2) cells.  First, we assessed whether 
sustained KGF stimulation led to constitutive activation of ERK and AKT in 
RIE(FGFR2) cells. Surprisingly, KGF stimulation did not increase the steady-state 
level of ERK phosphorylation levels in RIE(FGFR2) cells (Fig. 2-6B). As expected, 
since activated H-Ras(61L) did not increase AKT phosphorylation in RIE-1 cells, 
while H-Ras(61L) did increase AKT phosphorylation in NIH 3T3 fibroblasts (Fig. 2-
4B), no increase in AKT activity was seen in RIE(FGFR2) cells. However, we did find 
that sustained KGF increased cyclin D1 protein expression levels in RIE(FGFR2) 
cells. Cyclin D1 forms a complex with cyclin-dependent kinases CDK4/6 and 
phosphorylates and inactivates the retinoblastoma tumor suppressor protein (Rb). 
Thus, we further assessed if the increased cyclin D1 protein levels in RIE(FGFR2) 
cells stimulated with KGF corresponded to hyperphosphorylation and inactivation of 
Rb. Immunoblot analyses with phospho-specific Rb antibody that recognizes the 
phosphorylated and inactive form of Rb revealed that KGF stimulation caused Rb 
hyperphosphorylation in RIE(FGFR2) cells (Fig. 2-6B).  
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Figure 2-6. KGF stimulation induces morphologic transformation and 
increases cyclin D1 protein levels in FGFR2 IIIb C2-transformed, but not 
control, RIE-1 cells. 
A. RIE-1 cells stably infected with either the empty vector or encoding FGFR2 IIIb 
C2 were maintained in growth medium supplemented either 0.1% bovine serum 
albumin (Vehicle) or 50 ng/ml KGF and changes in cell morphology were evaluated 
after two days. B. RIE-1 cells stably expressing the indicated proteins were treated 
with either vehicle or 50 ng/ml KGF.  After 48 h, cell lysates were prepared and 
analyzed by immunoblot analyses for activated ERK and AKT. Cyclin D1 protein 
expression was determined by immunoblotting with cyclin D1 antibody and Rb 
inactivation was determined by immunoblotting with a phospho specific Rb (Ser 780) 
antibody. 
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G. FGFR2 IIIb C2-transformed RIE-1 Cells Show Enhanced ERK Activity, 
Increased Cyclin D1 Protein Levels, and Upregulation Of EGFR Autocrine 
Loop in Confluent Cultures, But Not in Sub-Confluent Cultures.  
  We observed that FGFR2 IIIb C2 but not Ras caused distinct growth 
promoting activities for fibroblasts and epithelial cells at different cell densities (Fig. 
2-3C).  Thus, we compared the signaling activity of RIE(FGFR2) and control 
RIE(vector) cells at subconfluent (~70% confluency) and post-confluent densities.  
For these analyses, the cultures were evaluated either three days after subculturing 
(for sub-confluent cultures) or after 12 days (for confluent cultures) and harvested for 
immunoblot analyses.  We observed sustained ERK, but not AKT, activation and 
increased cyclin D1 protein levels in confluent but not in sub-confluent RIE(FGFR2) 
cells (Fig. 2-7A).  Thus, sustained and elevated ERK activation may be required to 
facilitate the density-independent growth of RIE(FGFR2) cells.   
  One of the important traits that distinguish cancer cells from normal cells is 
the acquisition of self-sufficiency in growth signals by creating an autocrine signaling 
loop (104).  Therefore, we next examined the possibility that autocrine growth factors 
might be induced in confluent but not in sub-confluent RIE(FGFR2) cells. For these 
analyses, either RIE(vector) cells or RIE(FGFR2) cells maintained in culture until 
they reached 70% confluence (three days post plating) or for 12 days when cells had 
maintained at confluent density for eight days.  The conditioned media were then 
harvested from these cultures and added to parental RIE-1 cells. While conditioned 
medium from confluent RIE(FGFR2) cultures (designated D12 FGFR2-CM) caused 
morphologic transformation and cell scattering when added to parental RIE-1 cells, 
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conditioned medium from sub-confluent RIE(FGFR2) cultures (designated D3 
FGFR2-CM) showed no activity (Fig. 2-7B). In contrast, conditioned medium from 
either confluent or sub-confluent RIE(vector) cells did not induce transformation of 
parental RIE-1 cells.   
  Previously, our lab and others observed Ras caused upregulated expression 
and secretion of the transforming growth factor alpha (TGFα) epidermal growth 
factor receptor (EGFR) ligand that activated an EGFR-dependent autocrine growth 
and morphologic transformation in RIE-1 cells (72, 105)  Thus, we examined the 
possibility that an EGFR autocrine signaling loop might be upregulated in confluent 
RIE(FGFR2) cells. We observed that treatment with the gefitinib EGFR-specific 
kinase inhibitor as well as with U0126 prevented the morphologic transformation of 
parental RIE-1 cells caused by conditioned medium from confluent RIE(FGFR2) 
cells (Fig. 2-7C). Thus, FGFR2 IIIb caused the upregulation of an EGFR-dependent 
autocrine signaling loop in confluent, but not subconfluent, RIE-1 cells. 
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Figure 2-7. FGFR2 IIIb C2-transformed RIE-1 cells show enhanced ERK activity, 
increased cyclin D1 protein levels, and upregulation of an EGFR-dependent 
autocrine loop in confluent, but not sub-confluent, cultures. 
A. RIE-1 cells stably expressing the indicated proteins were plated and cultured in 
growth media for either 3 or 12 days. Sub-confluent (cultured for 3 days) or confluent 
(cultured for 12 days) RIE-1 cultures were harvested and analyzed for activated ERK 
and  AKT, and cyclin D1 protein levels by immunoblot analyses as described above  
B. RIE-1 cells stably infected with the empty vector or encoding FGFR2 IIIb were 
plated in growth medium. After 3 (D3) or 12 (D12) days after plating, conditioned 
medium from either vector control (Vector–CM) or FGFR2 IIIb C2-transformed RIE-1 
cells (FGFR2-CM) were collected and added to parental RIE-1 cells. Cells were 
photographed after 36 h. C. The gefitinib EGFR-specific kinase inhibitor and U0126 
prevented the morphologic transformation of parental RIE-1 cells caused by D12 
FGFR2-CM. 
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 V. Discussion 
  We identified FGFR2 IIIb C2 as a transforming gene expressed in human 
breast carcinoma cells. Although FGFR2 IIIb is expressed exclusively in normal 
epithelial cells, the majority of studies evaluating FGFR2 IIIb transformation have 
been done in fibroblasts (38, 39, 86). Since fibroblasts express FGFR2 IIIb ligands, 
the analyses of FGFR2 IIIb transformation in fibroblasts are complicated by an 
autocrine mechanism.  Since cell type-specific differences exist in mechanisms of 
cellular transformation and oncogenesis, we have compared FGFR2 IIIb C2 
transforming and signaling activities in NIH 3T3 fibroblasts and RIE-1 epithelial cells.  
Our observations suggest that FGFR2 IIIb-mediated transformation of epithelial cells 
may involve ligand-independent signaling that is independent of Ras activation, but 
additionally does require upregulation of an EGFR-dependent autocrine growth loop. 
  Previous studies found low expression of the C1 isoform of FGFR2 IIIb in 
normal mammary epithelial cells, with greatly elevated C1, as well as C2 and C3, 
expression in SUM-52 human breast cancer cells (68).  We extended these 
observations and found enhanced FGFR2 IIIb C1, C2 and C3 expression in 7 of 9 
breast carcinoma cell lines evaluated, when compared to the levels seen in 
immortalized MCF-10A human breast epithelial cell line.  Interestingly, the two cell 
lines that lacked FGFR2 IIIb expression harbor mutationally-activated Ras.  FGFR2 
IIIb C3 exhibited higher transforming activity when expressed in NIH 3T3 fibroblasts 
(39) or in H16N2 immortalized human mammary epithelial cells (40).  We have 
determined that FGFR2 IIIb C2 also displays greater transforming potency than 
FGFR2 IIIb C1 (data not shown).  Hence, increased expression of C2 and C3 may 
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contribute to the aberrant growth of breast carcinoma cells.  Furthermore, we 
identified expression of the mesenchymal-specific FGFR2 IIIc isoform in invasive 
breast carcinomas.  A similar switch from FGFR2 IIIb to IIIc has been observed in a 
rat prostate tumor progression model, where IIIc expression promoted progression 
to malignant tumors which were independent of the stroma (83).  Our cell line 
observations are consistent with a previous study that found a shift to IIIc expression 
in more advanced tumor stages (93).  We also found that expression of FGFR2 IIIc 
correlated with an epithelial-mesenchymal transition (EMT), as indicated by the loss 
of epithelial (E-cadherin) and gain of mesenchymal (N-cadherin and vimentin) 
protein expression. Since FGFR expression has been shown to promote EMT (75), 
perhaps the enhanced expression of FGFR2 IIIc in invasive breast carcinomas may 
promote EMT and increased tumor cell invasion.  Expression of FGFR2 IIIc may 
also render breast cancer cells independent of stromal cell-derived ligands.    
  Although FGFR2 IIIb C2 expression induced focus formation and soft agar 
growth of both NIH 3T3 fibroblasts and RIE-1 epithelial cells, only NIH 3T3 
fibroblasts were morphologically transformed by FGFR2 IIIb C2. However, when we 
treated RIE(FGFR2) cells with exogenous KGF, RIE(FGFR2) cells became 
morphologically transformed. These data indicate that FGFR2 IIIb-induced 
morphologic transformation is dependent on stromal cell-derived KGF.  In addition, 
we found that FGFR2 IIIb C2 caused upregulation of cyclin D1 protein levels in NIH 
3T3 fibroblasts but not RIE-1 cells.  However, KGF stimulation did increase cyclin D1 
protein levels, leading to inactivation of the Rb tumor suppressor.  These 
observations indicate that FGFR2 IIIb can induce growth transformation of epithelial 
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cells in a ligand-independent manner, but that paracrine stimulation by stromal cell-
derived KGF will also contribute to FGFR2 IIIb C2-mediated transformation of 
epithelial cells.  It has become clear that fibroblasts can regulate adjacent epithelia 
by secretion of growth factors and direct epithelial-mesenchymal interactions. In 
particular, several lines of evidences indicate that fibroblasts within the tumor stroma, 
so called carcinoma-associated fibroblasts (CAFs), possess distinct biological 
properties from normal fibroblasts and play a role as a key modifier of cancer 
initiation and progression  (106-109). Several oncogenic signals, including TGF-β, 
hepatocyte growth factor (HGF) and stromal cell-derived factor 1 (SDF-1) were 
shown to be upregulated in CAFs compared with normal fibroblasts (110). It is 
possible that KGF might be also upregulated in CAFs and aberrantly activate 
FGFR2 IIIb in adjacent epithelial cells and contribute to cancer development. 
  Since KGF-stimulated FGFR2 IIIb C2-transformed cells showed 
characteristics that resembled Ras-transformed RIE-1 cells, the enhanced 
transformation caused by KGF is likely to involve activation of Ras.  However, unlike 
mutant Ras-transformed RIE-1 cells, KGF stimulation did not cause activation of 
ERK in FGFR2 IIIb C2-transformed RIE-1 cells.  This difference may reflect a 
qualitative or quantitative difference in effector utilization by mutationally activated 
Ras when compared to upstream activation of endogenous wild type Ras.  The 
signaling mechanisms for ligand-independent growth transformation are not clear, 
but the absence of Ras activation in FGFR2 IIIb C2-transformed RIE-1 cells 
suggests that it does not involve Ras-mediated signaling.  Other FGFR2 IIIb C2 
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signaling activities that may facilitate growth transformation include activation of PLC 
gamma and stimulation of second messenger production.   
  We observed that FGFR2 IIIb C2 caused distinct growth-promoting properties 
in RIE-1 cells dependent on cell density (Fig. 2-3C). At subconfluent cell densities, 
we did not observe activation of ERK and upregulation of cyclin D1 in RIE(FGFR2) 
cells.  In contrast, at confluent cell densities, FGFR2 IIIb C2 increased ERK activity 
and cyclin D1 protein levels in RIE-1 cells.  We determined that confluent 
RIE(FGFR2) cells secreted factors that caused EGFR-dependent morphologic 
transformation of RIE-1 cells. We showed previously that activated Ras caused 
upregulation of EGF family ligands that were necessary for growth and morphologic 
transformation of RIE-1 cells (72, 105).  Conventionally, signaling activities are 
analyzed when cells are subconfluent and exponentially growing. However, our data 
indicate that cell density can be an important factor for determining signaling activity. 
Thus, our observations emphasize the importance of evaluating signaling activity in 
a same context where biological activity is obtained.  Differences in oncogene-
mediated signaling when evaluated in exponentially growing cells in cell culture 
versus a tumor mass where cells are at “confluent” cell densities, and in contact with 
stromal tissue, may account for why the potent inhibitory activities seen with signal 
transduction inhibitors have not reliably mirrored activities against a tumor mass.   
  In summary, our studies provide further validation of a positive role for the 
tumor-associated expression of the IIIb C2 splice variant of FGFR 2 in breast cancer 
growth.  Additionally, our studies support both ligand-independent and stromal cell 
derived ligand-dependent mechanisms by which FGFR2 IIIb may promote 
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oncogenesis in epithelial cells.  Our future studies will focus on elucidation of the 
ligand-independent, Ras-independent mechanisms of FGFR2 IIIb transformation. 
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Chapter 3: Aberrant Receptor Internalization and Enhanced FRS2-Dependent 
Signaling Contributes to the Ligand-Independent Transforming Activity of 
the Fibroblast Growth Factor Receptor 2 IIIb C3 isoform 
I. Abstract  
  Alternative gene splicing generates variants of fibroblast growth factor 
receptor 2 (FGFR2) IIIb that differ in the length of carboxyl-terminal sequences 
(designated C1, C2 and C3) and preferential expression of C2 and C3 isoforms is 
associated with oncogenesis. C2 and C3 lack the 34 or 53 carboxyl-terminal 
residues of C1, respectively, and we determined that progressive loss of carboxyl-
terminus sequences enhanced the transforming potency of FGFR2 IIIb.  The highly 
transforming C3 variant lacks five tyrosine residues present in C1 and we found that 
the loss of Y770 alone enhanced FGFR2 IIIb C1 transforming activity. Furthermore, 
concurrent mutation of Y770 and L773 in the 770YXXL motif cooperated to disrupt 
FGFR2 IIIb C1 internalization and enhance transforming activity, similar to that seen 
with the C3 isoform. We also determined that the Y770F mutation decreased PLCγ 
activity, but enhanced ligand-independent fibroblast growth factor receptor substrate 
2 (FRS2) activation, which was required for transformation.  Our data support a dual 
mechanism where loss of Y770 impairs receptor internalization and promotes ligand-
independent activation of FRS2, contributing to the enhanced transforming activity of 
FGFR2 IIIb C3. 
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II. Introduction 
Fibroblast growth factors (FGFs) comprise a large family of structurally related 
growth factors (22 human members) that mediate a variety of cellular responses that 
include cell proliferation, differentiation, migration, and angiogenesis (1-3, 84).  The 
activities of FGFs are mediated by their binding to a family of four receptor tyrosine 
kinases (RTKs), designated FGFR1-4.  FGFRs are comprised of an extracellular 
domain that consists of two or three immunoglobulin (Ig)-like domains, a single 
transmembrane domain and an intracellular catalytic tyrosine kinase domain and 
flanking regulatory sequences (Fig. 1A).  
 An important feature and mode of regulation of FGFR2 function is that 
structural variants of FGFR2 are generated by numerous alternative gene splicing 
events that generate transcripts that encode proteins altered in both the extracellular 
and intracellular regions of the FGFR2.  To date, more than 20 alternative splicing 
variants of FGFR2 have been identified. The first major splicing event occurs in the 
second half of the third Ig-like domain (designated Ig-III domain). Tissue-specific 
inclusion of either exon IIIb or exon IIIc that encode for the second half of the Ig-III 
domain generates either the epithelial cell-specific IIIb or mesenchymal cell-specific 
IIIc isoforms.  This alternative splicing determines the ligand binding specificity of 
FGFR2. While FGFR2 IIIb (also called keratinocyte growth factor receptor; KGFR) 
binds FGF7 (also called KGF) and FGF10, but not FGF2, FGFR2 IIIc (also called 
BEK) binds FGF2, but not FGF7 and FGF10.  
The second major splicing occurs in sequences that encode the carboxyl-
terminus of FGFR2. To date, at least three splice variants of FGFR2 IIIb that differ in 
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their carboxyl-terminal sequences have been identified (designated C1, C2 and C3) 
(39). The C2-type carboxyl-terminus is 34 amino-acid shorter than the C1-type 
carboxyl-terminus and C3-type carboxyl-terminus is 19 amino-acid shorter than C2-
type carboxyl-terminus. (Fig. 1A). These sequence differences result in differential 
retention of tyrosine residues that may serve as sites of receptor 
autophosphorylation and docking sites for cytoplasmic signaling proteins.  
 Previous study found that expression of the C3 isoform was increased in 
gastric cancer cell lines (39). We also observed enhanced expression of C2 and C3 
isoforms in a majority of human breast carcinoma cell lines when compared to non-
transformed MCF-10A human mammary epithelial cells (J.Y. Cha, G.W. Reuther, 
Q.T. Lambert and C.J. Der, submitted for publication), suggesting that aberrant 
expression of the C2 or C3 splicing variants may contribute to cancer development. 
Furthermore, the C3 variant that lacks carboxyl-terminal sequences was shown to 
be more transforming than the C1 variant when expressed ectopically in NIH 3T3 
fibroblasts and human mammary epithelial cells (39, 40). However, whether C2 
variant is more (or less) transforming than the C1 (or C3) variant has not been 
determined. Furthermore, the mechanism(s) for the enhanced transforming activity 
of the C3 variant that lacks carboxyl-terminal sequences remains to be elucidated. 
Like other RTKs, FGFRs are activated by ligand-induced dimerization, 
causing stimulation of their intrinsic tyrosine kinase activity, tyrosine 
autophophorylation, and recruitment of signaling proteins to specific phosphorylated 
tyrosine residues in their cytoplasmic carboxyl-termini.  The two best characterized 
downstream signaling components of FGFRs are phospholipase C-γ (PLCγ) and 
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FGF receptor substrate 2 (FRS2). In FGFR1, Y766 in the carboxyl-terminus is the 
major autophosphorylation site on FGFR1 and serves as a binding site for the Src 
homology 2 (SH2) domain of PLCγ, resulting in tyrosine phosphorylation of PLCγ 
(45, 111). Phosphorylation and activation of  PLCγ leads to stimulation of 
phosphatidylinositol (PI) hydrolysis and the generation of the two second 
messengers, diacylglycerol and Ins(1,4,5)P3. These two second messengers cause 
the activation of protein kinase C and the Ca2+ release from intracellular stores, 
respectively (46). The Y766 residue in FGFR1 is well conserved in all four FGFR 
family members and corresponds to Y770 in FGFR2 IIIb (Fig. 1B). Recently, it was 
shown that a Y770F missense mutant of FGFR2 IIIb C1 cannot bind and 
phosphorylate PLCγ (47). However, whether this mutant fails to activate PI 
hydrolysis, and whether altered PLCγ binding and activation contributes to FGFR 
transforming activity, remain unresolved. 
Unlike PLCγ, FRS2 association with FGFR is constitutive and independent of 
ligand stimulation and receptor phosphorylation (112).  FRS2 is a docking protein 
that binds to a conserved sequence within the juxtamembrane domain of FGFRs.  
Ligand-stimulated activation of FGFRs leads to phosphorylation of multiple tyrosine 
residues in the carboxyl-terminus of FRS2. One well-characterized FRS2 effector is 
the Grb2 adaptor protein which binds to tyrosine phosphorylated FRS2 via its SH2 
domain and forms a stable complex with the Sos Ras guanine nucleotide exchange 
factor.  This complex formation allows Sos to translocate to the plasma membrane 
where it can stimulate the exchange of GTP for GDP on the Ras small GTPase. 
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Activated Ras then activates the Raf-MEK-ERK mitogen-activated protein kinase 
(MAPK) cascade (1, 6). 
A balance between positive and negative signaling is critical for maintaining 
normal cell physiology. One mechanism of negative regulation of RTK signaling 
involves ligand-mediated receptor internalization and lysosomal degradation (13, 14). 
Therefore, disruption of receptor internalization could lead to aberrant receptor 
activation and contribute to the development of human disease including cancer. 
Interestingly, FGFR2 IIIb C1 contains two putative YXXΦ tyrosine-based sorting 
motifs (where X is any amino acid and Φ is a bulky hydrophobic amino acid) in 
carboxyl-terminal sequences (113). The C2-type carboxyl terminus lacks one YXXΦ 
motif (813YPHI), while the C3-type carboxyl terminus lacks two YXXΦ motifs 
(770YLDL and 813YPHI) (Fig. 1A), suggesting that the loss of the YXXΦ motif(s) might 
impair receptor internalization and contribute to the enhanced transforming activity of 
the FGFR2 IIIb C3 variant. 
To date, a detailed comparative analyses of the transforming potential of 
FGFR2 IIIb C1, C2 and C3 using the same cell system has not been done.  In the 
present study, we compared the transforming potency of FGFR2 IIIb C1, C2 and C3 
splicing variants and found that the C3 variant is considerably more transforming 
than the C2 variant, and the C2 variant is modestly enhanced in transforming activity 
when compared to the weakly transforming C1 variant.  We determined that one 
mechanism for the enhanced transforming activity of FGFR2 IIIb C3 involves loss of 
the 770YLDL sorting motif and impaired internalization. In addition, we determined 
that mutation of Y770 led to a loss of PLCγ activation, but a gain of ligand-
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independent FRS2 activation. Finally, we found that FRS2 activity was required for 
the enhanced transforming activity of FGFR2 IIIb C1 mutant receptors that lack 
Y770. Taken together, our data support a model where the potent transforming 
activity of the FGFR2 IIIb C3 splice variant is mediated, in part, by a mechanism 
involving loss of the 770YLDL motif, resulting in impaired receptor internalization and 
enhanced FRS2 signaling.  
III. Materials and methods 
Plasmid expression vectors 
 Human FGFR2 IIIb C1, C2 and C3 cDNA sequences were generated by PCR 
amplification from a T-47D breast cancer cell cDNA library and subsequently cloned 
into the pBabe-puro retrovirus mammalian expression vector (5'-SalI and 3'-BamHI 
sites). The FGFR2 IIIb C2 (QST) cDNA sequence (deletion of FGFR2 IIIb C1 
residues 789-822) was created by PCR amplification from FGFR2 IIIb C1 cDNA 
sequence and cloned into pBabe-puro (5'-SalI and 3'-BamHI sites).  Additional cDNA 
sequences encoding misssense mutations were created by site-directed 
mutagenesis using the QuikChange site-directed mutagenesis kit (Stratagene) and 
verified by DNA sequencing. Oligonucleotides designed to create the appropriate 
mutations to encode the indicated amino acid substitutions are as follows: 5'- 
CACAACCAATGAGGAATTCTTGGACCTCAGCCAACC-3' (Y770F); 5'-
GCCAACCTCTCGAACAGTTTTCACCTAGTTACCCTG-3' (Y780F); 5'-
CAGTATTCACCTAGTTTCCCTGACACAAGAAG-3' (Y784F); 5'-CCA 
GACCCCATGCCTTTCGAACCATGCCTTCCT-3' (Y806F); 5'-
CATGCCTTCCTCAGTTTCCACACATAAACGGC-3' (Y813F); 5'-
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GAGGAATTCTTGGACGCCAGCCAACCTCTCGAACAG-3' (Y770F/L773A); 5'-
CCAATGAGGAAGCCTTGGACGCCAGCCAACCTCTCG-3' (Y770A/L773A); 5'-
GAGGAATACTTGGACGCCAGCCAACCTCTCG-3' (L773A); 5'-
GCACAAGCTGACCGCACGTATCGCCGCGCGGAGACAGG-3' 
(K421A/P424A/L425A). 
Cell culture and transformation assays 
  Rat-1 and RIE-1 cells were maintained in Dulbecco’s modified minimum essential 
medium (DMEM-H) supplemented with 10% fetal calf serum. For secondary focus 
formation assays, Rat-1 and RIE-1 cells were stably-infected with pBabe-puro 
constructs encoding wild type FGFR2 IIIb isoforms and missense mutants of FGFR2 
IIIb C1. Expression of ectopically-introduced FGFR2 IIIb C1 proteins was determined 
by immunoblot analyses with anti-FGFR2 antibody (sc-122; Santa Cruz 
Biotechnology).  After infection, cells were selected in growth medium supplemented 
with puromycin (2 µg/ml). Drug resistant colonies were pooled and replated into 60 
mm dishes and maintained in growth medium for 2-3 weeks. Cells were then fixed 
and stained with crystal violet. To determine anchorage-independent growth 
potential, Rat-1 cells stably expressing either the pBabe-puro empty vector or 
encoding various FGFR2 IIIb proteins were suspended in 0.4% bacto-agar in growth 
medium at 5 x 104 cells per 60 mm dish. The single cell suspensions were layered 
on top of 0.6% bacto-agar in growth media. After 2-3 weeks, colonies were stained 
with 2 mg/ml MTT (tetrazolium salt 3,[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) and the average number of colonies on duplicate 
dishes was calculated. 
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Internalization assays 
 Rat-1 cells that stably express either wild type or mutant FGFR2 IIIb proteins were 
serum-starved for 20 h and then incubated with either vehicle (BSA) or 50 ng/ml 
KGF (R&D systems) for 40 min at 37ºC to allow internalization. Cells were then fixed 
(4% paraformaldehyde in PBS), washed, and permeabilized (0.1% Triton X-100). 
Next, cells were immunostained with rabbit polyclonal FGFR2 antibody (sc-122; 
Santa Cruz Biotechnology) to determine FGFR2 IIIb subcellular location by confocal 
microscope. To quantify receptor internalization, the number of positive 
internalization cells was counted under the confocal microscope. Positive 
internalization was scored only in cases where all surface staining was lost and 
almost all receptors were internalized to punctuate vesicular structure. The average 
number of positive internalization cells on three independent assays was calculated 
and 100 to 200 cells were examined for each independent assay.  
Signaling analyses   
To determine PLCγ activation, cells were lysed and then analyzed for tyrosine-
phosphorylated PLCγ by immunoprecipitation with anti-PLCγ antibody (sc-7290, 
clone E-12; Santa Cruz Biotechnology) followed by immunoblotting with anti-
phosphotyrosine antibody (#05-321, clone 4G10; Upstate Biotechnology). Then, the 
same membrane was stripped and reprobed with PLCγ antibody for total PLCγ 
expression. PI hydrolysis assays were performed to measure PLCγ activity as we 
have described previously (114). Briefly, Rat-1 cells stably expressing either wild 
type FGFR2 IIIb C1 or 770F mutant were labeled with myo-[3H] inositol in inositol-
free medium. Then, cells were stimulated with either KGF, vehicle (BSA, negative 
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control), thrombin (positive control) or lysophosphatidic acid (LPA; positive control) 
for 20 min in medium supplemented with 10 mM LiCl. Accumulation of [3H]inositol 
phosphates was quantitated as described previously (114). To determine FRS2 
activation, cells were lysed and then analyzed for tyrosine-phosphorylated FRS2 by 
immunoprecipitation with anti-FRS2 antibody (sc-8318; Santa Cruz Biotechnology) 
followed by immunoblotting with anti-phosphotyrosine antibody. To determine ERK 
activation, cells were lysed and then analyzed for active ERK by immunoblot 
analyses with antibody specifically detect phosporylated ERK (#9106; Cell Signaling 
Technology). The same membrane was stripped and reprobed with anti-ERK 
antibody (#9102; Cell Signaling Technology) for total ERK expression. 
IV. Results 
A. Loss of carboxyl-terminal sequences enhances FGFR2 IIIb transforming 
potency.   
Three splice variants of FGFR2 IIIb that differ in their carboxyl-terminal 
sequences have been identified (C1, C2 and C3) (39). The C2-type carboxyl -
terminus is 34 amino- acid shorter than the C1-type carboxyl-terminus, and C3-type 
carboxyl-terminus is 19 amino-acid shorter than C2-type carboxyl-terminus, resulting 
in the progressive loss of tyrosine residues (Fig. 3-1A). Previous reports 
demonstrated that FGFR2 IIIb C3 is more transforming than FGFR2 IIIb C1 in NIH 
3T3 fibroblasts and human mammary epithelial cells (39, 40). However, whether the 
FGFR2 IIIb C2 variant is more (or less) transforming than the FGFR2 IIIb C3 (or C1) 
variant has not been determined.  Since we recently identified the C2 variant in a 
biological screen for novel oncogenes expressed in breast cancer (J.Y. Cha, G.W. 
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Reuther, Q.T. Lambert and C.J. Der, submitted for publication), we initiated studies 
to compare the transforming potencies of C1, C2 and C3 in the same cell systems. 
To determine the role of carboxyl-terminal sequences in FGFR2 IIIb 
transformation, we compared the transforming potency of FGFR2 IIIb C1, C2 and C3 
variants by examining two aspects of growth transformation, loss of density-
dependent growth inhibition and acquisition of anchorage-independent growth 
potential. For these analyses, we established Rat-1 rat fibroblasts and RIE-1 rat 
intestinal epithelial cells stably expressing the FGFR2 IIIb C1, C2 or C3 variants and 
performed secondary focus formation and soft agar growth transformation assays. 
First, we compared the ability of the three FGFR2 IIIb variants to induce loss of 
density-dependent growth inhibition by quantitating the appearance of foci of 
multilayered cells in confluent cultures.  Cells stably-transfected with the empty 
vector or expressing the C1 variant exhibited no focus-forming activity.   In contrast, 
we found that cells expressing the C2 variant exhibited limited focus-forming activity, 
whereas the C3 variant caused significantly greater focus-forming activity than the 
C2 variant in RIE-1 (Fig. 3-1C) as well as Rat-1 (data not shown) cells. Second, we 
compared the ability of three FGFR2 IIIb variants to promote anchorage-
independent growth by soft agar assay. Consistent with their relative focus-forming 
potencies, the C3 variant induced 3.7-fold more soft agar colonies than the C2 
variant, and the C2 variant induced 2.1-fold great formation of soft agar colonies 
than C1 variant in Rat-1 cells (Fig. 3-1D). The same hierarchy of transformation 
potency was also seen in soft agar colony formation analyses of RIE-1 and MCF-
10A human breast epithelial cells (data not shown). These data indicate that multiple 
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Figure 3-1. Loss of carboxyl-terminal sequences enhances FGFR2 IIIb 
transforming potency. 
A. Carboxyl-terminal sequence comparison of three FGFR2 IIIb splice variants (C1, 
C2, C3).  Known or putative phosphorylated tyrosine residues are indicated.  B. 
Conservation of carboxyl-terminal tyrosines in FGFR family members.  Of the five 
tyrosine residues present in the C1 but not C3 variant of FGFR2, only Y770 (Y766 in 
FGFR1) and Y780 (Y776 in FGFR1) are conserved in all four receptors.  Receptor 
autophosphorylation of Y770 of FGFR2 IIIb (analogous to Y766 of FGFR1 and Y760 
of FGFR3) creates a recognition site for the SH2 domain of PLCγ.  C. Loss of 
carboxyl-terminal sequences enhances FGFR2-induced focus formation in RIE-1 
cells. Mass populations of RIE-1 cells that stably express the indicated FGFR2 IIIb 
carboxyl-terminal splice variants were assayed for focus-forming activity using a 
secondary focus formation assay. Cells were plated and allowed to grow for 21 days, 
and then the appearance of foci of transformed cells was monitored.  The cultures 
were fixed and stained with crystal violet and focus-forming activity was quantitated. 
D. Loss of carboxyl-terminal sequences enhances FGFR2-induced soft agar growth 
of Rat-1 cells.  Mass populations of Rat-1 cells that stably-expressed the indicated 
FGFR2 variants were assayed for their ability to grow in soft agar. The number of 
colonies was quantitated after 21 days.  
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carboxyl-terminal sequences function as negative regulators of FGFR2 IIIb 
transforming activity, with the loss of residues within the region spanning 769 to 788 
causing the most significant activation of transforming activity.  
 
B. Mutation of Y770F alone activates FGFR2 IIIb C1 transforming activity 
  Next, we determined the mechanism(s) for the enhanced transforming activity 
of FGFR2 IIIb variants lacking carboxyl-terminal sequences.  The carboxyl-terminal 
domain tyrosine residues of RTKs are sites of autophosphorylation and critical for 
their cytoplasmic signaling and growth regulatory activities.  The C3 variant lacks 
five tyrosine residues (Y770, Y780, Y784, Y806, Y813), while the C2 variant lacks 
two tyrosine residues (Y806, Y813) present in the C1 isoform (Fig. 3-1A). We 
speculated that the loss of specific tyrosine residue(s) might account for the 
enhanced transforming activity of the C2 and (or) C3 variants. To address this 
possibility, we introduced phenylalanine substitutions at each of the five tyrosine 
residues (Y770F, Y780F, Y784F, Y806F, Y813F) of the carboxyl-terminus of the 
weakly transforming C1 variant. Since loss of multiple tyrosine residues might be 
required for enhanced transforming activity, we also generated double (F2; 
Y813/806F), triple (F3; Y813/806/784F), quadruple (F4; Y813/806/784/770F) and 
quintuple (F5; Y813/806/784/780/Y770F) mutants. We then established mass 
populations of Rat-1 cells that stably-expressed wild type and mutant FGFR2 IIIb C1 
proteins and compared their transforming potency by evaluating anchorage-
independent growth potential in soft agar assays (Figs. 3-2A and 3-2B). We found 
that the Y770F mutation alone promoted colony formation in soft agar (~600 
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colonies per dish), while receptors with the Y780F, Y784F, Y806F or Y813F 
mutations showed the same weak colony forming activity (~200 colonies per dish) as 
cells expressing the wild type (WT) FGFR2 IIIb C1 receptor (Figs. 3-2A and 3-2B). In 
addition, we found that the F2 double or F3 triple mutant receptors showed the same 
transforming potency as WT FGFR2 IIIb C1 (Fig. 3-2B), while the F4 quadruple and 
F5 quintuple mutants that included the Y770F mutation promoted colony formation in 
soft agar to the same extent as the Y770F single mutant (Fig. 3-2B). To exclude the 
possibility that the enhanced transforming potency caused by the Y770F mutation 
might be due to greater expression, we analyzed the steady-state level of protein 
expression of all FGFR2 IIIb C1 proteins tested above by immunoblot analyses with 
an anti-FGFR2 antibody generated against a carboxyl-terminal sequence found only 
in the C1 isoform, and therefore, cannot recognize expression of the C2 and C3 
variants. We found that all FGFR2 IIIb mutants were expressed at a similar level as 
WT FGFR2 IIIb C1 (Fig. 3-2C). Together, these results indicate that loss of the Y770 
residue, but not other tyrosine residues (Y780, Y784, Y806 and Y813), contributes to 
the increased transforming potency of the C3 variant that lacks Y770 residue. 
However, since the C2 variant does retain the Y770 residue (Fig. 3-1A), the loss of 
the Y770 residue is not the basis for the increased transforming activity of the C2 
variant. 
 It is notable that the C2 variant lacks 34 carboxyl-terminal residues found in 
the C1 variant, but additionally, is also divergent from the C1 variant for three amino 
acids at positions 779, 783 and 787 (Fig. 3-1A). While the C1 variant contains 
779Q/783S/787T, the C2 variant contains 779P/783C/787P. 
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Figure 3-2. Mutation of Y770F alone activates FGFR2 IIIb C1 transforming 
activity. 
A. Rat-1 cells that stably expressed the indicated FGFR2 IIIb proteins were assayed 
for their ability to grow in soft agar. Cells were suspended in 0.4% soft agar and 
photographed 21 days after plating. B. The number of colonies was quantitated after 
21 days. Data shown are the average of duplicate dishes, with the bars indicating 
standard deviation, and are representative of two independent experiments. C. Rat-1 
cells that stably express the indicated FGFR2 IIIb proteins were assayed for their 
FGFR2 IIIb protein expression levels by immunoblot analyses with FGFR2 antibody 
against a peptide sequence in the FGFR2 IIIb C1 carboxyl-terminal sequence. This 
sequence has been deleted in the FGFR2 IIIb C2 and FGFR2 IIIb C3 variants; 
therefore, we cannot determine the level of expression of these two isoforms with 
this antibody.  Blot analysis with anti-beta actin was done to verify equivalent total 
protein loading. 
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Therefore, we speculated that differences in these three amino acids might 
contribute to the increased transforming potency of the C2 variant. To address this 
possibility, we generated a truncation mutant of C1 variant that has same length as 
C2 variant but contains the 779Q/783S/787T sequence (designated C2 (QST)) 
rather than the 779P/783C/787P sequence. We found that this C2 (QST) mutant 
exhibited a similar transforming potency as the C2 variant (Fig. 3-2B), indicating that 
the loss of the carboxyl-terminal 34 amino acids (from 789 residue to 822 residue), 
and not differences in 779, 783 and 787 residues is responsible for increased 
transforming potency of C2 variant.  
C. The 770YXXL motif is required for ligand-stimulated FGFR2 IIIb C1 
internalization. 
Next, we sought to determine how mutation of the Y770 residue enhanced 
FGFR2 IIIb C3 transforming activity. Interestingly, the Y770 residue and flanking 
sequences (770YLDL) correspond to the YXXΦ motif (Φ = bulky hydrophobic residue) 
that is known to be the major determinate for endocytosis of many transmembrane 
proteins (113). Consistent with this possibility, mutation of the analogous tyrosine 
residue in FGFR1 (Y766F) resulted in decreased receptor internalization, and 
decreased ligand-induced receptor downregulation and degradation (115).  However, 
another study found that a Y770F mutation did not cause impaired FGFR2 IIIb 
internalization (47). Thus, a clear role for the 770YXXL motif in FGFR2 IIIb receptor 
internalization is presently unresolved.   One possible resolution to the apparently 
opposing conclusions with FGFR1 and FGFR2 may be that, since there is evidence 
that the tyrosine residue of the YXXΦ sorting motif can be substituted with aromatic 
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amino acids such as phenylalanine or tryptophan (116-118), we postulated that if 
Y770 is substituted with an alanine instead of phenylalanine, the YXXΦ sorting 
signal might be disrupted. Alternatively, it is also possible that both the Y770 and 
L773 residues of 770YXXL motif might be required for FGFR2 internalization, and that 
concurrent mutation of both residues will be required to disrupt its function. 
To determine whether the Y770 and/or L773 residues are required for FGFR2 
IIIb C1 internalization, we generated mutant cDNA sequences encoding four FGFR2 
IIIb C1 missense mutants (Y770F, Y770F/L773A, Y770A/L773A and L773A) and 
compared the ability of WT and mutant receptors to undergo ligand-stimulated 
internalization.  For these analyses, Rat-1 cells that stably-expressed WT or mutant 
FGFR2 IIIb C1 proteins were stimulated with either vehicle (BSA) or 50 ng/ml KGF 
and immunostained with anti-FGFR2 antibody to determine the subcellular 
localization of receptors. In unstimulated cells, the WT and all four mutant receptors 
were found on the cell surface as well as in the intracellular compartment (Fig. 3-3B). 
After 40 min of KGF stimulation, the majority of the WT receptor (~89% internalized) 
was internalized to punctuate vesicular structure (Figs. 3-3A and 3-3B). We found 
that the Y770F mutation slightly impaired the ability of FGFR2 IIIb C1 to internalize 
(~71% internalized), while the L773A substitution caused a more strongly impaired 
ability of FGFR2 IIIb C1 to internalize (~42% internalized) (Figs. 3-3A and 3-3B). 
These data indicate that although both Y770 and L773 residues contribute to FGFR2 
IIIb C1 internalization, the L773 residue is more critical than the Y770 residue for 
FGFR2 IIIb C1 internalization. We also found that the Y770F/L773A (~23% 
internalized) double mutant more strongly impaired the ability of FGFR2 IIIb C1 to 
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internalize when compared to the Y770F or L773A single mutations (Figs. 3-3A and 
3-3B), indicating that both Y770 and L773 are required for efficient ligand-stimulated 
FGFR2 IIIb C1 internalization. In addition, the Y770F/L773A (~23% internalized) and 
Y770A/L773A (~26% internalized) double mutants showed similar abilities to 
internalize, indicating that Y770 cannot be replaced with an aromatic acid such as 
phenylalanine (Fig. 3-3).  
D. Loss of Y and L of 770YXXL motif cooperates to enhance 
transformation.   
We next determined whether disruption of 770YXXL motif to cause impaired 
internalization correlated directly with an enhanced transforming activity of FGFR2 
IIIb C1. For these analyses, we established Rat-1 cells that stably-expressed WT 
and mutant FGFR2 IIIb C1 proteins (Y770F, Y770F/L773A, Y770A/L773A and 
L773A) and compared transforming potency by colony formation in soft agar assays. 
Although the L773A mutant (~42% internalized) showed greater impairment in 
internalization when compared to Y770F mutant (~71% internalized) (Fig. 3-3A), the 
L773A mutant (~4-fold more transforming than WT) showed slightly weaker 
transforming activity than Y770F mutant (~6-fold more transforming than WT) (Fig. 
3-4A). Nevertheless, we did observe a general correlation with the degree of 
impaired internalization, with both the Y770F/L773A and Y770A/L773A double 
mutants (~10-fold more transforming than WT) exhibiting higher transforming activity 
when compared to either single mutant (Fig. 3-4A), suggesting that concurrent loss 
of the tyrosine and leucine residues of the 770YXXL motif cooperate to enhance the 
transforming activity of the carboxyl-terminus truncated FGFR2 IIIb.
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Figure 3-3. The 770YXXL motif is required for ligand-stimulated FGFR2 IIIb C1 
internalization. 
A. Rat-1 cells that stably express the indicated FGFR2 IIIb proteins were serum-
starved for 20 h and then incubated with either vehicle (BSA) or 50 ng/ml KGF for 40 
min at 37ºC. The cells were fixed, permeabilized, and immunostained with anti-
FGFR2 antibody to determine FGFR2 IIIb subcellular location by confocal 
microscopy. B.  Quantification of the internalization of wild type and mutant FGFR2 
IIIb C1 proteins. Rat-1 cells that stably express the indicated FGFR2 IIIb proteins 
were serum-starved for 20 h and then incubated with either vehicle (BSA) or 50 
ng/ml KGF for 40 min at 37ºC.  Data are expressed as percentage of cells that 
internalized receptors with the bars indicating standard deviation and are 
representative of three independent experiments. 
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 To exclude the possibility that different expression level of proteins could have an 
effect on transforming potency, we determined all FGFR2 IIIb proteins tested above 
were expressed at comparable levels (Fig. 3-4B). 
 E. Loss of Y770 impairs ligand stimulated FGFR2 IIIb C1 activation of 
PLCγ.   
While the L773A mutant exhibited greater impairment in internalization than 
the Y770F mutant (Fig. 3-3A), the Y770F mutant showed greater transforming 
activity than the L773A mutant (Fig. 3-4A). These observations suggest that 
impaired receptor internalization as well as some other mechanism(s) might 
contribute to enhanced transforming activity of Y770F mutant. Interestingly, the 
Y770 residue that corresponds to the 770YXXL protein sorting motif was also shown 
to be a binding site for PLCγ (45, 111).  Recently, it was shown that a Y770F 
missense mutant of FGFR2 IIIb C1 cannot bind and phosphorylate PLCγ, and 
impaired, rather than enhanced, ligand-stimulated mitogenic activity (47). While they 
showed that this mutation impaired KGF-stimulated ERK activation, whether this 
mutant fails to activate PI hydrolysis was not determined.  To further evaluate the 
role of Y770F in FGFR2 IIIb regulation of PLCγ signaling and transforming activity, 
and the consequences of mutation of other 770YXXL motif residues, we first 
determined whether these mutations decreased ligand-stimulated PLCγ 
phosphorylation. Once FGFR is stimulated and autophosphorylated, the SH2 
domains of PLCγ bind to tyrosine phosphorylated FGFR.  Binding of PLCγ to the 
activated FGFR facilitates its own tyrosine phosphorylation by the FGFR (4). To 
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determine if loss of Y770 causes decreased tyrosine phosphorylation of PLCγ, Rat-1 
cells stably-expressing a series of FGFR2 IIIb C1 mutants (Y770F, Y770F/L773A, 
Y770A/L773A and L773A), as well as the WT C1, C2 and C3 variants, were 
stimulated with either KGF (50 ng/ml) or vehicle (BSA in PBS) for 20 min. The cells 
were then lysed and immunoprecipitated with PLCγ antibody followed by 
immunoblot analyses with phosphotyrosine antibody. In unstimulated cells, none of 
the FGFR2 IIIb proteins evaluated showed elevated tyrosine phosphorylation of 
endogenous PLCγ.  However, after stimulation with KGF, as expected the WT 
FGFR2 IIIb C1 and C2, and not the C3 variants showed increased tyrosine 
phosphorylated PLCγ.  Interestingly, we observed that the WT C2 variant showed 
more strongly tyrosine phosphorylated PLCγ when compared to WT C1.  Moreover, 
we found that all three FGFR2 IIIb C1 mutants that lack the Y770 residue (Y770F, 
Y770F/L773A, and Y770A/L773A) failed to exhibit elevated tyrosine-phosphorylated 
PLCγ, while the L773A mutant retained the ability to stimulate tyrosine 
phosphorylation of PLCγ (Fig. 3-5A). Since tyrosine phosphorylation of PLCγ is 
essential for its activation it was expected that the Y770F mutant receptor would not 
activate PLCγ.  To test this idea directly, [3H]inositol phosphate accumulation was 
quantified in cells expressing either WT FGFR2 IIIb C1 or the Y770F mutant 
receptor.  Both thrombin and LPA promoted [3H]inostiol phosphate accumulation in 
Rat-1 cells expressing empty vector, but no endogenous response to KGF was 
observed (Fig. 3-5B). 
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Figure 3-4. Mutation of the Y and L residues of the 770YXXL motif cooperates to 
enhance FGFR2 IIIb C1 induction of anchorage-independent growth 
transformation. 
A. FGFR2 IIIb C1 770YXXL motif mutants exhibit enhanced colony formation in soft 
agar.  Rat-1 cells that stably express the indicated FGFR2 IIIb proteins were 
suspended in 0.4% soft agar and allowed to grow for 14 days before the number of 
colonies was quantitated. Data shown are the average of duplicate dishes, with the 
bars indicating standard deviation, and are representative of three independent 
experiments. B. Wild type and 770YXXL motif mutants of FGFR2 IIIb C1 are stably-
expressed at comparable levels. Rat-1 cells that stably-expressed the indicated 
FGFR2 IIIb proteins were assayed for their FGFR2 IIIb protein expression levels by 
immunoblot analyses with anti-FGFR2 antibody.  Total cell lysates were also blotted 
with anti-β-actin to verify equivalent total protein. 
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Stable expression of the wild type form of the C1 receptor conferred a marked 
[3H]inositol phosphate response to KGF.  In contrast, KGF-promoted [3H]inositol 
phosphate accumulation was not observed in Y770F mutant receptor-expressing 
cells although responses to thrombin and LPA were retained.  Taken together, these 
data suggest that Y770 is required for activation of PLCγ by FGFR2 IIIb, and the 
loss of capacity to promote inositol lipid hydrolysis might contribute to enhanced 
transforming activity of the C3 variant that lacks Y770. 
 
F.Loss of Y770 of FGFR2 C1 induces sustained activation of FRS2, but not 
ERK.   
PLCγ-mediated signaling is generally considered to promote mitogenesis and 
growth (119-121). Thus, the fact that Y770F enhances FGFR2 IIIb C1 transforming 
activity, yet results in the loss of PLCγ activation, argues that mutation of Y770 may 
affect other signaling activities that promote growth transformation. One possible 
explanation for this paradoxical observation is that PLCγ might compete with other 
FGFR2 IIIb effectors for binding to FGFR2 IIIb. By abolishing PLCγ binding, the 
Y770F mutation might relieve steric hindrance for other FGFR2 IIIb effectors and 
facilitate their binding to FGFR2 IIIb. Consequently, loss of PLCγ binding caused by 
the Y770F mutation may indirectly promote the activation of other FGFR2 IIIb 
effector pathways. Aside from PLCγ, the FRS2 proteins represent the next best-
characterized effectors of FGFR signaling. Therefore, we determined whether the 
mutation of Y770 altered FGFR2 IIIb activation of FRS2. For these analyses,  Rat-1 
cells stably-expressing WT or mutants of FGFR2 IIIb C1, as well as the WT C2 and 
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C3 variants, were stimulated for 20 min with either KGF (50 ng/ml) or vehicle. The 
cells were then lysed and immunoprecipitated with either anti-FRS2 antibody or anti-
phospho-tyrosine antibody followed by immunonblot analyses using either anti- 
phospho-tyrosine or anti-FRS2 antibody, respectively. After stimulation with KGF, all 
three FGFR2 IIIb variants (C1 WT, C2 and C3) showed increased levels of robustly 
tyrosine-phosphorylated FRS2. In addition, the Y770F and Y770A/L773A mutants 
tyrosine-phosphorylated FRS2 to a similar extent as was seen with the WT C1, C2 
and C3 variants (Fig. 3-6A). In the absence of KGF, although the WT C1 and C2 
variants that contain the Y770 residue did not exhibit increased tyrosine-
phosphorylated FRS2, the C3 variant that lacks the Y770 residue showed 
constitutively tyrosine-phosphorylated FRS2 (Figs. 3-6A and 3-6B). Furthermore, all 
three mutants that lack Y770 residue (Y770F, Y770F/L773A, and Y770A/L773A) 
showed constitutively tyrosine-phosphorylated FRS2 in the absence of KGF 
stimulation (Figs. 3-6A and 3-6B). These data indicate that the loss of Y770 
promotes constitutive, ligand-independent activation of FRS2 to enhance FGFR2 IIIb 
transforming activity. 
Next, we determined whether the loss of Y770 further activated downstream 
signaling by FRS2. Once FRS2 is tyrosine- phosphorylated, it forms a complex with 
the Grb2 adaptor protein and the Sos guanine nucleotide exchange factor and 
activator of Ras.  The best-characterized effector pathway of Ras is the Raf-MEK-
ERK MAPK. Thus, we examined whether loss of Y770F led to activation of ERK 
MAPK. For these analyses, we utilized immunoblot analyses with a phospho-specific 
antibody that recognizes the phosphorylated and activated forms of ERK1 and ERK2.  
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Figure 3-5. Mutation of Y770 impairs ligand-stimulated FGFR2 IIIb C1-
dependent activation of PLCγ. 
A. Mutation of Y770 but not L773 impairs KGF-stimulated phosphorylation of 
endogenous PLCγ.  Rat-1 cells stably expressing indicated FGFR2 IIIb proteins were 
serum-starved for 20 h and stimulated with either vehicle or 50 ng/ml KGF for 30 min. 
Tyrosine phosphorylated and total PLCγ protein was determined by 
immunoprecipitation with anti-PLCγ antibody followed by immunoblotting with anti-
phosphotyrosine (P-Tyr) antibody or with anti-PLCγ antibody, respectively. Data 
shown are representative of three independent experiments.  B. Mutation of Y770 
impairs KGF-stimulated formation of inositol phosphates. Rat-1 cells stably-
expressing the indicated wild type (WT) or mutant FGFR2 IIIb C1 proteins were 
serum-starved for 20 h and stimulated with vehicle (basal), or with 100 or 200 ng/ml 
KGF, 1 or 10 μM thrombin or lysophophatidic acid (LPA) (positive controls) and 
[3H]inositol phosphate (IP) accumulation was measured to assess PLCγ activity.  
Data shown are representative of three independent assays. 
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After stimulation with KGF for 20 min, all three FGFR2 IIIb variants (WT C1, C2 and 
C3) and mutants (Y770F, Y770F/L773A, and Y770A/L773A) phosphorylated ERK to 
a similar extent (data not shown). However, in the absence of KGF, none of the 
FGFR2 IIIb proteins tested above caused sustained activation of ERK (Fig. 3-6B). 
Together, these data suggest that the mutation of Y770 caused constitutive 
activation of FRS2, but did not promote FRS2-mediated activation of ERK. 
G. FRS2 activity is required for increased FGFR2 IIIb C1 transforming activity 
by Y770F mutation but not L773A mutation.   
Next, we determined whether FRS2 activity is required for increased 
transforming activity of FGFR2 IIIb C1 by Y770F mutation and/or L773A mutation. 
For these analyses, we generated mutants of FGFR2 IIIb C1 that cannot bind and 
activate FRS2. Previously, it was demonstrated that the phosphotyrosine-binding 
(PTB) domain of the FRS2 constitutively binds to juxtamembrane region of FGFR1 
(112). Utilizing alanine scanning mutagenesis, the specific amino acid residues in 
juxtamembrane region of FGFR1 that are responsible for FRS2 binding were 
identified. When K419, P422, and L423 residues in juxtamembrane region were 
substituted with alanine, interaction between FGFR1 and the FRS2 was strongly 
diminished, resulting in decreased tyrosine phosphorylation of FRS2 (112). Since 
K419, P422, and L423 residues in juxtamembrane region of FGFR1 are well 
conserved in FGFR2 IIIb, we constructed a FGFR2 IIIb (K421A/P424A/L425A) 
mutant (designated as ΔFRS2) that is analogous to the FGFR1 
(K419A/P422A/L423A) mutant. We first determined whether the ΔFRS2 mutation  
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Figure 3-6. Mutation of Y770 of FGFR2 IIIb C1 causes sustained activation of 
FRS2. 
A. Like FGFR2 IIIb C3, Y770 mutants of FGFR2 IIIb C1 exhibit ligand-independent 
phosphorylation of FRS2.  Rat-1 cells stably expressing indicated FGFR2 IIIb 
proteins were serum starved for 20 h and stimulated with either vehicle (control) or 
50 ng/ml KGF for 30 min. FRS2 activity was determined by immunoprecipitation (IP) 
with anti-FRS2 antibody followed by immunoblotting (IB) with anti-phosphotyrosine 
(P-Tyr) antibody. B. Like FGFR2 IIIb C3, Y770 mutants of FGFR2 IIIb C1 cause 
ligand-independent sustained activation of FRS2 but not ERK. Rat-1 cells stably 
expressing indicated proteins were analyzed for FRS2 activity by 
immunoprecipitation (IP) with either anti-FRS2 antibody or anti-phospho-tyrosine 
antibody followed by immunoblotting (IB) with either phospho-tyrosine anibody or 
FRS2 antibody, respectively. ERK activation was determined by immunoblot 
analyses using antibody that recognize activated, phosphorylated form of ERK. Data 
shown are representative of three independent experiments. 
 
 92
could abolish FRS2 activation. As expected, when the ΔFRS2 mutation was 
introduced into two existing mutants, Y770F (designated as (designated as 
Y770F/L773A/ΔFRS2), the increased FRS2 tyrosine-phosphorylation caused by the 
Y770F mutation was completely abolished (Fig. 3-7A).  
Since we determined that the ΔFRS2 mutation blocked FRS2 tyrosine-
phosphorylation, we further examined whether the ΔFRS2 mutation can diminish the 
enhanced transforming activity of the Y770F or Y770F/L773A mutants.  Consistent 
with our observation in Fig. 4, Y770F showed ~7-fold, while Y770F/L773A showed 
~11-fold higher transforming activity compared with WT C1 (Fig. 3-7B). When we 
introduced the ΔFRS2 mutation into the Y770F mutant, the resulting Y770F/ΔFRS2 
mutant showed similar transforming activity as WT C1 (Fig. 3-7B). This observation 
indicates that the enhanced transforming potency by Y770F mutation is dependent 
on FRS2 activity. However, when we introduced ΔFRS2 mutation in Y770F/L773A 
mutant, although the ΔFRS2 mutation partially diminished the transforming activity of 
the Y770F/L773A mutant, Y770F/L773A/ΔFRS2 still exhibited ~4-fold greater 
transforming potency than WT C1 (Fig. 3-7B). In fact, Y770F/L773A/ΔFRS2 mutant 
showed similar transforming potency as L773A mutant (Fig. 3-7B), suggesting that 
ΔFRS2 only abolishes enhanced transforming activity caused by theY770F but not 
L773A mutation. Taken together, these data indicate that increased FRS2 activation 
is required for the increased transforming activity caused by the Y770F but not 
L773A mutation.  
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Figure 3-7. FRS2 activity is required for increased FGFR2 IIIb C1 transforming 
activity caused by the Y770F but not L773A mutation. 
A. Mutation of the FRS2 binding site impairs FGFR2 IIIb YXXL mutant activation of 
FRS2.  Rat-1 cells stably expressing indicated FGFR2 IIIb proteins were grown to 
confluence and were lysed and FRS2 activity was determined as described above. 
Total FRS2 protein levels were determined by immunoprecipitation (IP) with anti-
FRS2 antibody followed by immunoblotting (IB) with anti-FRS2 antibody. Total cell 
lyasates were analysed to determine stable FGFR2 IIIb protein expression levels by 
immunoblot analyses with anti-FGFR2 antibody. ΔFRS2 corresponds to the 
K421A/P424A/L425A mutations in the FRS2 binding site. B. Mutation of the FRS2 
binding site impairs the transforming activity caused by the Y770F but not the L773A 
YXXL mutant of FGFR2 IIIb C1.  Rat-1 cells stably expressing the indicated FGFR2 
IIIb proteins were suspended in 0.4% soft agar and allowed to grow for about 14 
days before the number of colonies was quantitated. Data shown are the average of 
duplicate dishes, with the bars indicating standard deviation, and are representative 
of three independent experiments. 
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V. Discussion 
Although missense mutations of FGFR2 are found in human cancers 
(http://www.sanger.ac.uk/genetics/CGP/CellLines) (54), another mechanism of 
FGFR2 activation in cancer involves alternative gene splicing.  FGFR2 IIIb exists in 
at least three carboxyl-terminal variants, designated C1, C2 and C3, due to 
alternative gene splicing.  Increased expression of the C2 and C3 splice variants has 
been observed in human cancers, suggesting that differential expression of specific 
splice variants may contribute to oncogenesis.  A recent study identified frameshift 
mutations that caused premature truncation of the carboxyl terminal sequences 
lacking in FGFR2 IIIb C3, in endometrial cancers (54), supporting the importance of 
loss of carboxyl terminal sequences in FGFR2 activation in cancer.  In this study, we 
compared the transforming potency of the C1, C2 and C3 splicing variants of FGFR2 
IIIb and found that a hierarchy of transforming activity (C3>C2>C1) that correlated 
with progressive loss of carboxyl terminal sequences.  C2 and C3 lack two or five 
carboxyl terminal tyrosine residues, respectively, that are retained in C1 and we 
determined that loss of the Y770 alone significantly the enhanced transforming 
activity of FGFR2 IIIb C1.  This observation was unexpected since a previous study 
found that loss of Y770 impaired FGFR2 IIIb C1-mediated activation of the ERK 
MAPK cascade and stimulation of cell proliferation (47).  Since this residue is a key 
component of an established PLCγ binding site and a putative YXXL tyrosine-based 
sorting motif, we evaluated the consequences of mutation of 770YXXL motif on 
FGFR2 IIIb on PLCγ activation and receptor internalization. We found that disruption 
of the 770YXXL motif in the weakly transforming C1 variant impaired receptor 
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internalization and enhanced transforming potency. We also found that loss of Y770 
abolished PLCγ activity, but instead enhanced FRS2 activity. Together, we suggest 
a model (Fig. 3-8) for two distinct mechanisms where the loss of the 770YXXL motif 
contributes to the enhanced transforming potency of FGFR2 IIIb C3.  The loss of the 
770YXXL motif causes impaired ligand-stimulated receptor internalization to promote 
persistent ligand-independent signaling. In addition, loss of Y770 in the C3 variant 
abolishes PLCγ binding to FGFR2 IIIb, and consequently, may relieve steric 
hindrance and facilitate FGFR2 IIIb activation of FRS2-mediated signaling.  FRS2-
dependent signaling, independent of the ERK MAPK cascade, then promotes growth 
transformation. 
Our analyses, in several fibroblast and epithelial cell types (data not shown), 
showed that sequential loss of carboxyl-terminal sequences caused progressive 
enhancement in FGFR2 IIIb transforming activity, indicating that multiple carboxyl-
terminal tyrosine residues control negative regulators of FGFR2 IIIb biological 
activity.  However, the significantly greater transforming activity of the C3 variant, 
when compared to the C2 isoform, indicates the key importance of residues Y770, 
Y780 and/or Y784.  This would be consistent with the fact that, of the five Tyr 
residues found in the carboxyl terminus of FGFR2 IIIb C1, only Y770 and Y780 are 
conserved in all four FGFR family members (Fig. 3-1B).  Our mutational analyses of 
all five Tyr residues found that the loss of Y770 alone in C1 partially mimicked the 
enhanced transforming activity of the C3 isoform. When Y770 was mutated in 
combination with the remaining four tyrosine residues, no further enhancement in 
transforming activity was seen.  This suggests that the loss of non-tyrosine residues 
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 Figure 3-8. Role of altered signaling caused by deletion of the 770YXXL motif in 
FGFR2 IIIb C3 transforming activity. 
Based on our observations with missense mutations in the 770YXXL motif and FRS 
binding site of FGFR2 IIIb C1, we propose that the loss of 770YXXL sorting motif 
contributes significantly to the potent transforming activity of the C3 variant.  We 
propose that the 770YXXL motif serves two distinct functions in the C1 isoform.  First, 
it serves as a phosphorylation-dependent binding site for the SH2 domain of PLCγ, 
which promotes ligand-stimulated second messenger signaling.  Second, it serves 
as a protein sorting signal, similar to those found in other cell surface receptors, that 
promotes rapid receptor internalization and endocytosis, and lysosomal degradation.  
We also propose that the mutation of the tyrosine residue of the 770YXXL motif 
prevents PLCγ binding and activation.  FRS2 association with the FGFR2 receptor is 
phosphorylation-independent.  The loss of PLCγ binding may facilitate FGFR2 
phosphorylation and activation of FRS2. Consequently, the C3 variant exhibits 
increased, ligand-independent FRS2 activity that leads to enhanced transformation 
through and unidentified FRS2 effector(s).  Our results suggest that the best-
characterized FRS2 effector, Grb2 adaptor-mediated activation of Ras and the ERK 
MAPK cascade, is not the basis for FRS2-dependent transformation. 
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must also contribute to the potent transforming activity of the C3 variant.  
Previous mutational analyses of Y770 in FGFR2 IIIb showed that a Y770F 
mutation impaired PLCγ binding and phosphorylation (47) and we showed that the 
Y770F mutation impaired PLCγ regulation of phosphoinositide metabolism.  
However, the loss of PLCγ signaling alone seems an unlikely explanation for 
enhanced FGFR2 IIIb transforming activity. First, PLCγ activation has been 
generally considered to promote, rather than antagonize, growth. For example, 
overexpression of PLCγ was shown to promote growth transformation of NIH 3T3 
mouse and rat 3Y1 fibroblasts (121, 122). In addition, the analogous Y760F mutation 
in tumor-derived constitutively-activated mutants of FGFR3 (the K650E missense 
and the TEL-FGFR3 fusion protein) was shown to abolish PLCγ activation and 
inhibited their transforming activities in Ba/F3 mouse pro B cells (123), and it was 
concluded that PLCγ activation is required for FGFR3-mediated transformation. A 
similar conclusion was made for platelet-derived growth factor receptor activation of 
PLCγ, where selective loss of PLCγ activation resulted in loss of transforming activity 
(120).  On the other hand, it was shown that the Y766F mutation in FGFR1 
abolished ligand-stimulated PLCγ activation but not mitogenesis, as measured by 
DNA synthesis in L6 myoblasts (44, 45), suggesting that PLCγ activity is not 
required for FGFR1-mediated growth stimulation. These different conclusions for 
PLCγ regulation of cell proliferation may reflect cell context variations in PLCγ 
biological function as well as the different biological assays utilized.  Additionally, 
they may reflect distinct functions of FGFR isoforms and the likelihood that this 
tyrosine residue may regulate PLCγ–independent functions (124).   
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During the course of our studies, Ethier and colleagues reported that mutation 
of Y770 alone was not sufficient to enhance FGFR2 IIIb C1 growth transforming 
activity when assayed in HME mammary epithelial cells (125). One possible 
explanation for our different conclusions is that their transforming activities were 
characterized in a different cell type, with our studies focused on Rat-1 fibroblasts. 
Since fibroblasts but not epithelial cells, express the ligand (KGF/FGF7) for FGFR2 
IIIb, FGFR2 IIIb can be activated in fibroblasts by formation of autocrine signaling 
loop, but not in epithelial cells. In fact, we also found that the Y770F mutation did not 
increase FGFR2 IIIb C1 transforming activity when expressed in RIE-1 epithelial 
cells (data not shown).  These results underscore the striking cell context differences 
in the signaling activities important for FGFR2-stimulated growth transformation. 
In a similar study to our analyses, Miki and colleagues evaluated the 
consequences of Y to F mutations of Y780, Y784, Y806 or Y813 on the transforming 
activity of the mesenchymal cell-specific FGFR2 IIIc C1 isoform (86).  As with 
FGFR2 IIIc C1, carboxyl-terminal truncation and loss of the five Tyr residues and 
flanking sequences activate FGFR2 IIIc transforming activity.  However, their 
deletion analyses eliminated a role for Y770.  Instead, they found that mutation of 
either residue Y780, Y784 or Y813 alone caused the same activation of transforming 
activity as carboxyl-terminal truncation of the sequence including all five tyrosine 
residues.  Surprisingly, these activating substitutions did not increase receptor 
autophosphorylation or ERK activation, and the mechanism for increased 
transforming activity was not identified.  The basis for our different observations with 
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these tyrosine residues is not clear and may reflect functional differences in FGFR2 
IIIb and IIIc signaling. 
FGFR signaling is attenuated by receptor endocytosis and lysosomal 
degradation (126).  The “YLDL” endocytic motif is well-conserved in all four FGFRs 
and Y770 of FGFR2 IIIb corresponds to Y766 FGFR1 (Fig. 3-1B).  Previously, 
Sorokin et al. found that a Y766F mutant of FGFR1 resulted in decreased receptor 
internalization in L6 myoblasts and Ba/F3 hematopoietic cells (115). In contrast to 
this study, Ceridono et al. found that introduction of a Y770F mutation into FGFR2 
IIIb did not cause impaired internalization in HeLa cells (47). Since there are 
discrepancies between these studies and since these studies evaluated only the role 
of tyrosine but not leucine residue of YXXL motif, we examined the roles of both 
Y770 and L773 in KGF-stimulated internalization of FGFR2 IIIb.  In contrast to 
Ceridono et al., we found that the Y770F mutation disrupted FGFR2 IIIb 
internalization, although the degree of disruption was very weak and may account 
for the negative conclusion in the previous study. The discrepancy between our 
study and that of Ceridono et al. may also be due to the use of different cell types 
(Rat-1 fibroblasts versus HeLa cells) or to different experimental approaches for 
protein expression (stable infection versus transient transfection). Our internalization 
studies were done in the same cells used for our growth transformation analyses. 
The Y770F/L773A double mutation more strongly impaired FGFR2 IIIb 
internalization when compared to the Y770F or L773A single mutation, suggesting 
that both the Y and L residues of 770YXXL motif contribute to FGFR2 internalization. 
In addition to 770YLDL, there is another YXXΦ motif (813YPHI) in carboxyl-terminal 
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sequences of FGFR2 IIIb. The C2 variant lacks one YXXΦ motif (813YPHI), while the 
C3 variant lacks two YXXΦ  motifs (770YLDL and 813YPHI). We found that the 
Y813F/I816A mutations did not impair receptor internalization or enhance 
transforming potency (data not shown), suggesting that 770YLDL but not 813YPHI is 
critical for FGFR2 IIIb internalization.  Various mechanisms that cause impaired 
endocytosis of FGFR1, leading to prolonged membrane association and persistent 
signaling, have been described (127, 128). 
While we found that FGFR2 IIIb C1 mutants that lacked the Y770 residue 
(Y770F, Y770F/L773A and Y770A/L773A), as well as the C3 variant, showed 
enhanced FRS2 activity, Ceridono et al. found that the Y770F mutation diminished 
KGF-stimulated phosphorylation of FRS2. However, this previous analysis was done 
with transient activation rather than the sustained expression of FGFR2 IIIb done in 
our studies. It has been suggested that distinct biological outcomes can be elicited 
depending on the duration of signaling, and sustained but not transient activation of 
signaling is more critical for oncogenesis (129-131). Thus, the duration of FGFR2 
IIIb activation might account for the discrepancies between our and this previous 
study. In accordance with our study, Moffa et al. also found that stable expression of 
the FGFR2 IIIb C3 variant constitutively activated FRS2 (40).  To our surprise, 
although the mutation of Y770 induced sustained activation of FRS2, and we 
showed that loss of FRS2 binding impaired transformation, we found that increased 
FRS2 activation did not result in increased ERK activation. Although activation of the 
Ras-ERK cascade is a well-characterized function of FRS2 activation, other FRS2 
signaling activities have also been described that may account for the role of FRS2 
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in FGFR2 transformation.  Alternatively, we speculate that sustained activation of 
FRS2 may activate negative regulators of ERK such as MAPK phosphatases that 
can diminish ERK activity (132).  
In summary, our studies identified two distinct mechanisms regulated by the 
Y770 residue that contribute to the enhanced transforming potency of the highly 
transforming FGFR2 IIIb C3 variant. Since the loss of other tyrosine residues did not 
contribution to C1 transforming activity, our future studies will focus on defining the 
non-tyrosine residue-based mechanisms for the enhanced transforming potency of 
the C3 variant. Although we found that the C2 variant was more transforming than 
the C1 variant, loss of tyrosine residues does not appear to account for C2 
transforming activity, and therefore, we have not found a clear mechanistic basis for 
the enhanced transforming potency of C2 variant. Finally, we determined that 
increased FRS2 activation was necessary for enhanced transforming activity, but by 
a mechanism independent of increased ERK activation.  FRS2 possesses multiple 
tyrosine phosphorylation sites and can interact with other signaling proteins, 
including the Shp2 protein phosphatase and the Gab1 adaptor protein.  Thus, our 
future studies will include the determination of the critical signaling activities 
important for FRS2-mediated growth transformation. 
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Chapter 4: Conclusion and Future studies  
 
Fibroblast growth factors (FGFs) regulate normal cell morphogenesis during 
development by regulating cell proliferation, differentiation and migration (1, 2, 133).  
FGFs function by stimulating four cell surface receptor tyrosine kinases (FGFR1-4).  
FGFR activation then stimulates key cytoplasmic signaling networks that include the 
Ras-Raf-MEK-ERK mitogen-activated protein kinase cascade and the 
phosphatidylinositol 3-kinase (PI3K)-Akt cell survival pathways.  In light of the critical 
role of FGF-FGFR signaling in normal cell physiology, it is not unexpected that 
aberrant FGF-FGFR function is associated with human disease.  In particular, gain-
of-function missense mutations in FGFR1-3 have been linked to the impaired 
skeletal development and cancer.  Chromosome translocations that result in 
chimeric proteins that contain constitutively activated fragments of FGFR3 have also 
been identified.  Aberrant FGF and FGFR gene expression in cancer has also been 
seen.  In my studies of FGFR2 function, I have focused on yet another mechanism 
by which FGFR function can be altered to promote human oncogenesis (Figure 4-1).  
It is estimated that up to 60% of human genes undergo alternative gene splicing, 
resulting in the expression of structurally- and functionally-distinct proteins (134).  
Aberrant gene splicing, resulting in the inappropriate expression of a specific splice 
variant, has been found in human diseases such as thalassemia, cystic fibrosis and 
cancer.  My studies in Chapter Two are focused on FGFR2 splice variant expression 
that alters the ligand specificity and activation of FGFR2 and may contribute to tumor 
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cell invasion and metastasis.  My studies in Chapter Three involve the analyses of 
FGFR2 splice variants with altered cytoplasmic signaling to promote the uncontrolled 
proliferation of tumor cells.  
Cancer is a disease characterized by a population of cells that proliferate in 
an uncontrolled way, invade surrounding tissues and, in some cases, metastasize to 
distant organs of the body to form secondary tumors (104).  Tumor metastasis is the 
basis for the deadly aspects of this disease, and it remains one of the least 
understood aspects of cancer progression. The process of cancer metastasis 
consists of a series of sequential steps. After the initial transforming events and 
primary tumor formation, angiogenesis occurs to support the metabolic needs of 
primary tumors.  For tumor cells to metastasize, they must invade neighboring 
tissues. To invade efficiently, tumor cells often lose cell-cell adhesion and gain a 
fibroblastoid phenotype-a process known as epithelial-to-mesenchymal transition 
(EMT).  After invasion, tumor cells penetrate through the endothelial cell lining of 
blood vessels and enter into the body’s circulatory blood systems- a process called 
intravasation. Once tumor cells reach a new distal target organ, they escape from 
the blood vessels - a process called extravasation. In the new distal site, tumor cells 
initiate and maintain growth to form secondary tumors.  Based on my studies in 
Chapters two and three, I propose that two distinct FGFR2 alternative splicing 
events, which alter the primary sequence of the extracellular IgIII domain and 
cytoplasmic carboxyl-terminus, might be critical contributors of cancer progression 
(Figure 4-2).  
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Figure 4-1. Gene splicing regulation of FGFR2 function.  
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In chapter 2, we found that invasive breast carcinoma cells lost expression of the 
epithelial cell-specific FGFR2 IIIb isoform and gained expression of sthe normally 
mesenchymal cell-specific FGFR2 IIIc isoform. 
  In contrast, all, non-invasive breast carcinoma cells exclusively expressed 
only the FGFR2 IIIb isoform. An important future direction of these studies will be to 
determine whether FGFR2 IIIc expression is simply a biological marker for the 
breast cancer invasive phenotype or whether FGFR2 IIIc can in fact plays a causal 
role and promotes invasiveness. To address a causal role, we will determine 
whether forced expression of FGFR2 IIIc in non-invasive breast carcinoma cells can 
promote cell invasion.  However, since concurrent loss of FGFR2 IIIb expression 
may be needed, use of interfering RNA to silence FGFR2 IIIb expression may also 
be needed.  Since enforced overexpression could potentially generate artifacts, we 
will also determine whether endogenous FGFR2 IIIc expression in invasive breast 
cancers can play a role in carcinoma invasion. Two different approaches will be 
taken for this goal. Previously, Thiery and colleagues (81) demonstrated that FGF1 
stimulation of endogenous FGFR2 IIIb in rat bladder carcinoma cells induced a 
switch in expression from IIIb to IIIc. Therefore, we can determine if the stimulation 
of non-invasive breast carcinoma cells (T47D and MCF7 cells) with FGF1 causes 
IIIb to IIIc exon switching that is then accompanied by enhanced cell invasion.  A 
second approach can be to use antisense oligonucleotides to modify exon III splicing 
and determine whether switch from exon IIIb to IIIc can contribute to carcinoma 
invasion (135).   For example, Kole and colleagues used targeted oligonucleotides 
antisense to the 5'-splice site of bcl-x(L), an anti-apoptotic gene that is 
 106
overexpressed in various cancers, and shifted the splicing pattern of Bcl-x pre-
mRNA from Bcl-x(L) to Bcl-x(S), a pro-apoptotic splice variant (136). 
Another remaining question is why FGFR2 IIIb to IIIc exon switching occurs. 
One of possible explanation for this question is that the aberrant expression of a 
specific splice variant(s) endows cancer cells with a specific selective advantage in 
at different stages of tumor progression that reflect their dependence on their 
environment. Since primary tumor cells are surrounded by stromal tissue and 
fibroblasts that secret paracrine ligands for FGFR2 IIIb, the expression of IIIb might 
be the preferential form for non-invasive primary tumor cells (Figure 4-2). However, 
to invade to the adjacent tissues, cancer cells may need to be self-sufficient and 
independent of stromal tissue factors. Thus, the normally mesenchymal-specific IIIc 
form that can be stimulated by epithelial cell-expressed FGF ligands may favor 
cancer cell expression of this splice variant during tumor cell invasion. Similarly, 
when tumor cells are circulating in the blood, the IIIc variant might be the favorable 
splice form, since cancer cells still need to be stromal-independent. Alternatively, 
since blood cells may secret ligands for IIIc but not IIIb, it would be advantageous for 
tumor cells to express the IIIc to survive in the blood stream.  Finally, when cancer 
cells reach at a distant organ and form secondary tumors, cancer cell proliferation 
may favor IIIb expression that can be activated in its newly established 
microenvironment. To prove this hypothetical model, first, we can develop antibodies 
that specifically recognize either FGFR2 IIIb or IIIc isoform and determine the IIIb/IIIc 
expression level in different stage of cancer tissues from the breast cancer patients. 
Furthermore, we can determine the expression pattern of IIIb (FGF1 -3,-7,-10, and -
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22) and IIIc (FGF1, -2, -4, -6, -9, -17 and -18) ligands in breast carcinoma cells as 
well as the surrounding tissues using immunohistochemistry. We expect that 
invasive breast carcinoma cells may have increased expression of IIIc ligands to 
form an autocrine-siganling loop, while stromal cells surrounding the primary or 
secondary tumors may have increased expression of IIIb ligands.  Second, we can 
establish culture models that can mimic surrounding tissue of different stage of 
cancer cells (For example, primary tumors, invading cancer cells, and secondary 
tumors) and determine whether the environment of cancer cells can cause IIIb to IIIc 
(or IIIc to IIIb) exon switching.  
 It was shown that FGFR2 mutations in the linker region between the IgII and 
IgIII domains of FGFR2 (for example, S252W) allow the mesenchymally-expressed 
mutant FGFR2 IIIc to be activated by mesenchymal cell expressed ligands and the 
epithelial cell expressed mutant FGFR2 IIIb to be activated by epithelial cell 
expressed ligands, resulting in the creation of aberrant autocrine growth signaling 
loop (50, 51). It would be interesting to determine whether invasive breast cells have 
mutations that disrupt the ligand binding specificity. For example, the mutant FGFR2 
IIIb S252W that has same ligand binding specificity as FGFR2 IIIc, might promote 
cell invasion by acquiring self-sufficiency and stromal-independence.  
 In chapter 2, we found that loss of FGFR2 IIIb and gain of IIIc expression was 
correlated with loss of epithelial (E-cadherin) and gain of mesenchymal (N-cadherin 
and vimentin) protein expression in breast carcinoma cells. However, we have not 
determined whether FGFR2 IIIb to IIIc switch can induce EMT. Thus, in the future, 
we will determine whether ectopic expression of FGFR2 IIIc in non-invasive breast  
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Figure 4-2. Two distinct FGFR2 alternative splicing events, which alter the 
primary sequence of the extracellular IgIII domain and cytoplasmic carboxyl-
terminus, might be critical contributors of cancer progression.  
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carcinoma cells (T47D and MCF-7 cells) induces EMT. We will examine whether 
FGFR2 IIIc causes cells to lose expression of epithelial (E-cadherin and beta-catenin) 
and gain of expression of mesenchymal (fibronectin, vimentin and N-cadherin) 
proteins. In addition, we will test whether ectopic FGFR2 IIIc expressing-cells 
acquire fibroblastic morphology and enhanced cell migration.  If we find that FGFR2 
IIIc induces EMT, we will further determine the mechanism of FGFR2 IIIc-induced 
EMT. For example, we could examine the possibility that FGFR2 IIIc activity 
increases the expression of known EMT-inducers such as the Snail, Slug or Twist 
transcription factors.  Interestingly, genetic mutations of Twist and FGFR2 were 
shown to induce premature fusion of cranial sutures (craniosynostosis) (137), 
indicating that FGFR2 and Twist might share similar function.  
 The importance of epithelial-mesenchymal interactions is being increasingly 
appreciated in embryonic development and tumorigenesis. During tumorigenesis, 
aberrantly activated stromal cells can promote the proliferation of adjacent epithelial 
cells by enhanced secretion of paracrine factors and expression of ECM 
components. Conversely, genetic alterations in pre-cancerous epithelial cells can 
change the stromal microenvironment to favor epithelial tumorigenesis.  In chapter 
Two, we found that while FGFR2 IIIb induced growth transformation of epithelial 
cells in a ligand-independent manner, recombinant KGF stimulation further 
enhanced FGFR2 IIIb-mediated growth transformation of epithelial cells.  In future 
studies, we can determine the role of the stromal microenvironment in FGFR2 IIIb-
mediated epithelial tumorigenesis by utilizing human breast tumor xenograft models. 
For these analyses, carcinoma associated fibroblasts (CAFs) from breast carcinoma 
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patients or normal fibroblasts from the same patients would be mixed with FGFR2 
IIIb-transformed human mammary epithelial cells (HMECs) (designated as 
HMEC(FGFR2)) and inoculated in immunodeficient nude mice. If CAFs but not 
normal fibroblasts enhance tumor formation of HMEC(FGFR2), we would further 
determine which paracrine factors are up-regulated in CAFs.  It would also be 
interesting to determine whether transformed HMEC(FGFR2) can induce adjacent 
stromal microenvironment to undergo changes that may alter the normal epithelial-
mesenchymal interactions. For example, transformed HMEC(FGFR2) may induce 
adjacent normal fibroblasts to become activated CAFs that may secret increased 
KGF.  
 In Chapter Three, we found that the IIIb C3 variant is more transforming than 
the longer IIIb C2 variant, and the IIIb C2 is more transforming than the weakly 
transforming and longer IIIb C1 variant. These observations indicate that aberrant 
splicing that alter the FGFR2 carboxyl-terminus, that favor expression of the IIIb C2 
or IIIb C3 variant, might contribute to the tumorigenesis. Our other observation that 
enhanced IIIb C2 and IIIb C3 expression in non-invasive breast carcinoma cells 
compared to MCF-10A non-transformed cells also support this idea. However, since 
these studies only done in cell-based in vitro assay, in the future, we will extend 
theses studies to in vivo animal studies, where tumor-stromal cell interactions are in 
place.  
In summary, my studies further establish the importance of alternative gene 
splicing as a critical mechanism by which FGFR2 function is deregulated to promote 
human cancer development.  Current microarray gene expression analyses do not 
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detect alternative splicing of genes.  Recent genome sequencing surveys can 
identify missense mutation of genes as well as mutations that alter sequences.  
Therefore, these studies have not provided a rigorous evaluation of the importance 
of FGFR2 gene splicing in human cancers.  With the ongoing development of gene 
array technology to identify specific gene splice variants, these new approaches will 
help further define the importance of alternative splicing in FGFR2 deregulation in 
cancer.  AZD2171 is an oral, highly potent, and selective inhibitor of FGFR2.  A 
recent study determined that AZD2171 anti-tumor activity correlated with gastric 
tumor expression of carboxyl terminal-truncated FGFR2 splice variants that were 
constitutively phosphorylated, spontaneously dimerized and persistently activated 
(138). Thus, future studies that better establish the role of specific FGFR2 splice 
variants in cancer growth, together with the development of tools to detect splice 
variant expression in human cancers, may identify effective therapeutic applications 
of AXD2171 and other FGFR2 inhibitors for cancer treatment. 
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